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CHAPTER 1 
Introduction 
To understand what our next 5 years will look like in the cathlab, I think it 
is important to review how we came to where we are today. Interventional 
cardiology may well be one of the most explosive disciplines in the history 
of medicine. It is one of the rare practices that strives to obsolete itself at 
warp speed. What’s new and innovative today is gone tomorrow, as the 
next greatest innovation replaces it. I oftern marvel at how hard industry 
must work to come up with the next generation of what appears to be a 
perfectly acceptable device. Notwithstanding research in intervantional 
cardiology couldn’t be limited to new devices, drugs and techniques. 
Sometimes redefining a pathological entity, like for example coronary 
artery ectasia (CAE) could be extremely useful in order to correctly 
classify the several degrees of such coronaropathy and consequently 
identify a standardized therapeutical approach. 
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1. Structural interventions and their complications 
Aortic valve replacement (AVR) has been the mainstay of treatment of 
symptomatic severe aortic stenosis. The role of transcatheter aortic valve 
implantation (TAVI; also known as transcatheter AVR or TAVR) as an 
alternative to surgical aortic valve replacement (SAVR) is evolving. 
Through both rapidly increasing clinical experience and progressive 
improvement in TAVI devices (eg, lower profile systems to reduce 
vascular complications), TAVI outcomes have improved. Ongoing studies 
continue to scrutinize the risks of TAVI complications and continuing 
efforts seek to minimize these risks. 
Complications of TAVI will be considered in this topic commencing with 
immediate or periprocedural complications, which are usually apparent 
during or shortly after the procedure and moving to longer-term 
considerations. This topic will deal with periprocedural complications 
related to vascular access (including injury at the arterial access site, 
arterial tree trauma, and problems with vascular closure), valve 
deployment (including improper positioning, coronary compromise and 
annular rupture), valve function (including paravalvular leak), organ injury 
(including stroke, myocardial ischemia/injury, and acute kidney injury), 
and arrhythmic complications (including high degree heart block and atrial 
fibrillation) and late complications including aortic regurgitation and 
prosthetic valve thrombosis. 
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2. Peripheral arterial disease 
Peripheral arterial disease (PAD) refers to partial or complete occlusion of 
one or more non-coronary arteries that leads to compromised blood flow 
and ischemia. Numerous processes are involved in arterial stenosis, 
however, atherosclerosis remains the most common etiology. 
Remarkable technological advances in the past decade, along with patient 
preference, have shifted revascularization strategies from traditional open 
surgical approaches toward lower-morbidity percutaneous endovascular 
treatments. The availability of stents, more than any other advance, has 
fueled the growth of catheter-based procedures by improving the safety, 
durability, and predictability of percutaneous revascularization. 
Carotid artery stenting (CAS) is considered to be a reasonable alternative 
to carotid endarterectomy (CEA), particularly in patients at high risk for 
CEA. Also about lower limbs revascularization, several new devices and 
techniques, like drug-coated balloons, drug-eluting stents and directional 
atherectomy came up in last years. 
The performances of all these devices as well as their application to 
different anatomical settings is surely another interesting research field. 
3. Coronary arteries and their diseaseas 
Coronary field is probably the oldest one in interventional cardiology both 
in terms of practice and research. Although the latter is focusing more on 
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drugs, devices and imaging, in recent years also coronary physiology and 
physiopathology are a hot topic. But why forget normal and pathological 
coronary anatomy? Coronary artery ectasia (CAE) or coronary artery 
aneurysm is the aneurysmal dilatation of coronary artery. This condition 
has been defined as a dilatation with a diameter of 1.5 times the adjacent 
normal coronary artery based on CASS registry in 1983. This definition, 
which was proposed well before standardized quantitative coronary 
analysis (QCA) was developed, raises multiple issues and has so far 
negatively impacted our understanding about the prevalence and the 
clinical significance of this pathological condition. 
The current working definition impedes the diagnosis in patients with 
diffuse CAE in whom no reference diameter exists. These patients are not 
infrequent in practice. Moreover, the absence of reference normal coronary 
diameters against which establishing the diagnosis, forces interventional 
cardiologists to diagnose CAE only in the presence of self-evident and full-
blown cases. Although the clinical significance of CAE is not fully 
understood, largely due to under-recognition and the lack of a workable 
diagnostic algorithm, many studies have demonstrated that it is not a 
benign disorder and it is associated with a high risk of (recurrent) coronary 
events. In general, the absence of a specific treatment for these patients has 
led to systematic under recognition of the importance of this condition. 
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Under these premises, we should aim at establishing reference values for 
coronary arteries at invasive coronary angiogram by analysing with QCA 
a large cohort of healthy individuals who underwent invasive coronary 
angiogram for suspected, but not confirmed, coronary artery disease who 
present with uneventful cardiovascular clinical history, no established 
cardiac disorder, including valvular or muscle heart disease and without 
established atherosclerosis risk factor. 
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PART 1 
 
Structural interventions and their complications 
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CHAPTER 2 
Acute aortic dissection during ineffective attempt of 
transcatheter implant of a fully resheathable, respositionable 
and retrievable aortic valve 
Aortic injury is a rare but severe complication that may occur during 
transcatheter aortic valve implantation (TAVI). Few patients with type A 
dissection are treated surgically because of the high rate of postoperative 
mortality and neurological complications in this high-risk population; thoracic 
endovascular aortic repair is rare too, and technically challenging because of 
the anatomical variations of spiral type A aortic dissection. Sometimes a 
watchful waiting strategy could be the best solution. We have reported the 
case of an acute, extended aortic type A dissection occurred during a TAVI 
procedure, probably due to the rupture of the dedicated sheath, and 
conservatively managed. 
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Multiple fluoroscopies. Pop-out of an aortic bioprosthesis Direct Flow Medical®, after 
ineffective attempt to implant it (a); bioprosthesis retrieval through its specific 
dedicated basket (b); rupture of the sheath probably due to its overdistension after the 
engagement of the retrieval basket (c); angiographic control after surgical extraction 
of all the transcatheter device, followed by endoprosthesis and covered stent 
implantation (d); final aortographies: iatrogenic acute aortic dissection from pre-
carrefour tract of abdominal aorta, with exclusion of the left kidney (e) and retrograde 
extension till ascending aorta, without an evident proximal tear (f). 
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CHAPTER 3 
Feasibility and safety of early discharge after Transfemoral 
transcatheter aortic valve implantation – rationale and design 
of the FAST-TAVI registry 
Background. There is an increasing trend towards shorter hospital stays after 
transcatheter aortic valve implantation (TAVI), in particular for patients 
undergoing the procedure via transfemoral (TF) access. Preliminary data 
suggest that there exists a population of patients that can be discharged safely 
very early after TF-TAVI. However, current evidence is limited to few 
retrospective studies, encompassing relatively small sample sizes. 
Methods. The Feasibility And Safety of early discharge after Transfemoral 
TAVI (FAST-TAVI) registry is a prospective observational registry that will 
be conducted at 10 sites across Italy, the Netherlands and the UK. Patients will 
be included if they have been scheduled to undergo TF-TAVI with the 
balloon-expandable SAPIEN 3 transcatheter heart valve (THV; Edwards 
Lifesciences, Irvine, CA). The primary endpoint is a composite of all-cause 
mortality, vascular-access-related complications, permanent pacemaker 
implantation, stroke, re-hospitalisation due to cardiac reasons, kidney failure 
and major bleeding, occurring during the first 30 days after hospital discharge. 
Patients will be stratified according to whether they were high or low risk for 
early discharge (≤ 3 days) (following pre-specified criteria), and according to 
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whether or not they were discharged early. Secondary endpoints will include 
time-to event (Kaplan–Meier) analysis for the primary outcome and its 
individual components, analysis of the relative costs of early and late 
discharge, and changes in short- and long-term quality of life. Multivariate 
logistic regression will be used to identify factors that indicate that a patient 
may be suitable for early discharge. 
Discussion. The data gathered in the FAST-TAVI registry should help to 
clarify the safety of early discharge after TF-TAVI and to identify patient and 
procedural characteristics that make early discharge from hospital a safe and 
cost-effective strategy. 
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CHAPTER 4 
Prosthesis depth and conduction disturbances after last 
generation balloon-expandable transcatheter aortic valve 
Preliminary data on Sapien 3 valve (S3-THV) use for transcatheter aortic 
valve implantation have shown an increased permanent pacemaker 
implantation (PPMI) rate with respect to Sapien XT valve. Aim of this study 
was to investigate the role of S3-THV position in the left ventricular outflow 
tract (LVOT) on electrocardiographic changes suggestive of atrioventricular 
(ΔPR) and/or intraventricular conduction abnormalities and 30 days PPMI 
rate. 
Eighty-six consecutive patients treated with S3-THV were included in the 
study. All patients underwent clinical and electrocardiogram evaluation. Left 
ventricular outflow tract prosthesis depth was assessed by fluoroscopy and 
expressed quantitatively (mm) and as aorto-ventricular ratio (AVR). 
Eight patients (9.3%) needed PPMI at 30 days. A low AVR (≤60/40) predicted 
PPMI (OR = 6.09, 95% CI 1.19–31.01, p = 0.030) and resulted into higher 
PPMI rate, compared with higher AVR (30.0 vs. 6.6%, p = 0.017). For each 
millimetre increase in the LVOT prosthesis depth PPMI risk increased by 1.41 
times (95% CI 1.06–1.87, p = 0.017). In patients with low AVR, ΔPR was 
higher than in those with higher AVR (33.4 ± 56.7 vs. 12.1 ± 19.4 ms, p = 
0.021) and ΔPR was associated to LVOT prosthesis depth (β = 0.286, p = 
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0.009). Furthermore, ΔPR was associated with risk of PPMI (OR = 1.03, 95% 
CI 1.01–1.06, p = 0.024). 
 
A low AVR is associated to higher ΔPR and PPMI rates. The correlation 
between LVOT prosthesis depth with ΔPR and higher PPMI rate suggests the 
need of a careful S3-THV implantation.  
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CHAPTER 5 
Optimizing patient discharge management after transfemoral 
transcatheter aortic valve implantation: the multicenter 
european FAST-TAVI trial 
Aims. Treatment pathway optimization in TAVI should include timely patient 
discharge with a minimized risk for out-of-hospital adverse events. 
Methods and Results. We defined and validated the adequacy of a set of 
discharge criteria and their ability to properly predict timely and safe 
discharge after the intervention in a prospective, European, multicentre 
registry. 502 unselected patients were enrolled at 10 sites in 3 countries.  
 
The primary endpoint defined as a composite of all-cause mortality, vascular-
access-related complications, permanent pacemaker implantation, stroke, re-
hospitalisation due to cardiac reasons, kidney failure and major bleeding at 30 
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days was reached in 12.9% of patients (95%CI 11.3-16.5). The overall 30-day 
mortality was 1.1% (95%CI 0.2-2.0), and the rates of stroke/TIA 1.7% 
(95%CI -0.6 to 4.0), PPI 7.3% (95%CI 5.8-8.9), major vascular complications 
1.9% (95%CI 0.7-3.1), major/lifethreatening bleeding 2.4% (95%C 1.0-3.8) 
and cardiac rehospitalisation 3.7% (95%CI 1.4-6.0). Patients appropriately 
discharged early had a significantly lower risk of the primary endpoint (7.0 
vs. 26.4%; p < 0.001) which was reflected in some of its relevant components: 
stroke (0.0 vs. 2.8%; p = 0.015), PPI (4.3 vs. 15.9%; p < 0.001), major vascular 
complications (0.3 vs. 4.7%; p = 0.004) and major / life-threatening bleeding 
(0.3 vs. 6.5%; p < 0.001). 
 
Conclusions. We validated the appropriateness of a pre-specified set of risk 
criteria that allow for a safe and timely discharge. The rate of 30-day 
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complications did not reveal any risk increase with this strategy compared 
with the reported outcomes in major TAVI trials and registries. 
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CHAPTER 6 
Invasive electrophysiological evaluation for conduction delays 
prediction in last generation balloon-expandable TAVI 
TEXT 
The occurrence of atrioventricular (AV) and intraventricular (IV) conduction 
disturbances is still common after transcatheter aortic valve implantation 
(TAVI) and may lead to early permanent pacemaker implantation (PPMI); this 
represent one of the biggest limitations to the extension of the indication to 
intermediate-risk patients. A number of patient-related and procedure-related 
factors, including evidence of conduction system dysfunction, either pre-
existing right bundle branch block (RBBB) or AV block occurring at 
procedural time, valve type, prosthesis oversizing, increased septal wall 
thickness, and extensive calcification in the area of the non-coronary aortic 
cusp and/or left ventricle outflow tract (LVOT), have been recognized as 
being related to the risk of AV conduction defects requiring PPMI after TAVI. 
After preliminary findings that SAPIEN 3 Transcatheter Heart Valve (S3-
THV) (Edwards Lifesciences Inc., Irvine, California, USA) use was 
associated with increased PPMI rate compared with SAPIEN XT valve (XT-
THV) (17.0 vs. 11.0%) [1], a recent study confirmed the suggestion that a 
more aortic deployment may reduce the need for PPMI, defining 4.26 mm as 
a “safe” cut-off implantation depth in the LVOT with a PPMI risk increased 
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by 1.41 times for each mm increase in the prosthesis depth [2]. Aims of this 
study were to investigate the effects of TAVI with S3-THV on AV and IV 
conduction by electrophysiological study (EPS), and to individuate new 
potential predictors of such conduction disturbances. 
The study was approved by the “Campania Nord” Institutional Ethic Review 
Board (approval date 20/01/2016, registry number: CECN/376); all patients 
gave informed written consent for the procedures. A total of 48 consecutive 
patients with symptomatic aortic stenosis (25 males, mean age 81.3±4.4 years, 
mean logistic EuroSCORE 15.7 ± 10.3%, mean STS score mortality 24.9 ± 
9.0%) but without previous or new-onset atrial fibrillation or previous PPMI, 
underwent TAVI with the S3-THV at “Montevergine” Clinic, Mercogliano, 
Italy, between February and November 2016. All patients underwent high-
quality Multi-Detector Computed Tomography (MDCT) angiography 
evaluation of annulus sizing, as well as leaflets and LVOT calcium score (CS), 
using a software specifically customized to valve analysis (3mensio ValvesTM, 
version 4.1). If possible, the THVs were selected in a narrow sizing range of 
–5% (undersizing) to +10% (oversizing). According to previous literature 
findings, all the S3-THV had an “aortic deployment” with more than 60% of 
the prosthesis implanted above the virtual ring. EPS was performed 
immediately before the initial balloon aortic valvuloplasty (BAV) and 
immediately after S3-THV implantation, recording the main standard 
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parameters, i.e. Atrial-His (AH), His, His-Ventricle (HV), Wenckebach AV 
block point (WP) and Atrial-Ventricular Node Functional Refractory Period 
(AVNFRP). No patients received medications likely to have potential effect 
on the conduction system. ECG monitoring was performed during the 
procedure and continued for at least 72 h. Intra and periprocedural events were 
defined according to the Valve Academic Research Consortium (VARC) 2 
standardized criteria [3]. PPMI with class I or class IIa indication have been 
performed according to current guidelines [4]. Statistical analyses were 
performed using SPSS 16.0 (IBM,…, USA) and MedCalc 13.0. Continuous 
variables were expressed as absolute numbers and percentage or mean ± SD. 
Comparisons have been made by the paired or unpaired t test, as appropriate, 
in the case of normal distribution, or the Wilcoxon or Mann-Whitney U test, 
as appropriate, in the case of non-normal distribution. Categorical variables 
have been presented as counts and percentages and compared using Fisher’s 
exact or chi-square test, as appropriate. Univariate and multivariate logistic 
regression analysis have been performed to identify independent predictors of 
conduction disturbances detected by EPS. A two-sided p value of < 0.05 will 
be considered of statistical significance. 
A total of five patients (10.4%) needed PPMI after TAVI at 30 days follow-
up. No EPS variables resulted significantly prolonged after valve deployment, 
but in those patients who needed PPMI, ∆HV (80.2 ± 128.5 vs. 8.9 ± 11.2; P 
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< 0.001) and ∆WP (132.0 ± 198.3 vs. 29.7 ± 45.1; P = 0.005) were 
significantly longer. Notwithstanding ΔHV and ΔWP did not result associated 
with leaflets and LVOT CS as well as % prosthesis oversizing. 
The close anatomical relationship between the branching AV bundle and the 
aortic valvular complex provides an explanation for the observed increase in 
AV or IV disturbances after TAVI. Most changes occur as direct effects on 
the infra-Hisian conduction system, probably caused by direct pressure on the 
lower area of the prosthesis on the basal portion of the ventricular septum and 
the area involving the His-bundle. At present time there is no way to determine 
the likelihood of recovery or progression of conduction disorders after TAVI 
therefore, identifying a subgroup of patients with a high probability of 
developing a high-grade block, which might require PPMI during follow-up, 
is of the utmost importance. The only study which analyzed the effect of TAVI 
with balloon-expandable valves on the conduction system by performing an 
EPS, showed that HV interval and WP were significantly prolonged after XT-
THV implantation, but these conduction problems recovered before discharge 
[5]. According to the safer more aortic implantation technique, in our study 
the PPMI rate was comparable to XT-THV one (10.4%). Moreover, 
differently from Eksik findings, ΔHV and ΔWP used as early markers of 
conduction disturbances as well as new predictors of PPMI, so much so that 
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deriving data from EPS could provide to the valve team useful informations 
about the correct timing to safely remove the temporary PM. 
According to EPS evaluation, TAVI with S3-THV does not cause significant 
prolongation of AH, His, HV, WP, AVNFRP, also if HV and WP prolongation 
significantly predict PPMI. Moreover, a lower implantation depth in the 
LVOT provides a not different total PPMI rate from that reported for other 
balloon-expandable valves, independently from prosthesis oversizing and 
valvular complex calcification amount. 
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CHAPTER 7 
Impact of contrast mean osmolality on the risk of contrast-
induced nephropathy after transcatheter aortic valve 
implantation 
ABSTRACT 
Background and aims. Acute kidney injury (AKI) after transcatheter aortic 
valve implantation (TAVI) is frequent and associated with adverse outcomes 
and mortality. Aim of the present study was to investigate the relationship 
between contrast agent osmolality and periprocedural AKI during TAVI. 
Methods and Results. From 2011 to 2016, 412 consecutive patients not in 
dialysis treatment who underwent TAVI for symptomatic severe aortic 
stenosis (188 males, mean age 80.7 ± 5.8, mean logistic EuroSCORE 17.7 ± 
13.8%) were enrolled. According to osmolality of the different iodinated 
contrast agents (CAs) used for the procedure, the population was divided in 2 
groups: iso-osmolality contrast agent (IOCA group, n = 230) and low-
osmolality contrast agents (LOCA group, n = 182). Preoperatively, 175 
(42.5%) patients suffered from chronic kidney disease (eGFR < 60 mL/min), 
98/230 (42.6%) in IOCA vs. 77/182 (42.3%) in LOCA group (p = 0.951). 
However, a significant difference in postprocedural change of eGFR in IOCA 
group vs. LOCA group (+3.78 ± 17.27 vs. -3.09 ± 14.87 mL/min, respectively; 
p < 0.001). Furthermore, a lower percentage of patients developed any stage 
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of AKI in IOCA group (18/230, 7.8%) vs. LOCA group (21/182, 11.5%), 
although not statistically significant (p = 0.201). Importantly, at linear 
regression analysis, the use of IOCA resulted the only variable associated with 
increase in eGFR (beta 0.206, p < 0.001), and the association remained even 
when the amount of CA applied intraprocedurally, logistic EuroSCORE and 
blood transfusions were included in the multivariable model (beta 0.215, p < 
0.001). 
Conclusions. Strategies to prevent AKI in TAVI patients remain an important 
challenge. In this study we found that the use of IOCA have a favorable impact 
on renal function with respect to other CAs and thus should be considered 
especially for TAVI patient at higher risk for AKI.  
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INTRODUCTION 
Transcatheter aortic valve implantation (TAVI) for high-risk and inoperable 
patients with severe aortic stenosis (AS) is an emerging procedure in 
cardiovascular medicine. The applications of TAVI are also expanding to 
“off-label” indications in patients with intermediate risk, AS secondary to 
bicuspid valve disease, aortic regurgitation, aortic valve-in-valve procedures, 
and mitral valve interventions [1]. Little is known of the impact of TAVI on 
renal function. 
Patients undergoing TAVI nowadays are commonly very old and have a high 
prevalence of chronic kidney disease (CKD). Both the European System for 
Cardiac Operative Risk Evaluation (EuroSCORE) and the Society of Thoracic 
Surgeons (STS) score include renal function parameters to evaluate the risk of 
mortality in cardiac surgery. In fact, trying to avoid potential deterioration of 
renal function in patients with CKD has become an important argument for 
choosing TAVI rather than surgical aortic valve replacement in those cases. 
TAVI procedures involve the administration of contrast agent (CA), the 
systematic occurrence of short periods of extreme hypotension (rapid pacing, 
balloon valvuloplasty, and valve deployment), the manipulation of large 
catheters in the aorta of patients with a high prevalence of diffuse 
atherosclerosis with the risk of cholesterol embolization, and sometimes the 
occurrence of paravalvular aortic regurgitation with a reduction in diastolic 
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renal blood flow: all of them are potential risk factors for acute kidney injury 
(AKI).  
The use of different definitions of AKI (based on the RIFLE [Risk of renal 
dysfunction, Injury to the kidney, Failure of kidney function, Loss of kidney 
function, and End-stage kidney disease], VARC [Valve Academic Research 
Consortium]-1, and VARC-2 criteria), patient and procedural characteristics 
may explain the disparate incidences across the several series. A meta-analysis 
including 5,971 patients treated with TAVI shows that AKI occurred in 22.1% 
of patients and that those with AKI had a significant increase of early and 1-
year all-cause and cardiovascular mortality, myocardial infarction, life-
threatening bleeding, need for transfusion and dialysis [2]. In 2012, the VARC 
standardized the timing for the AKI diagnosis, extending from 72 hours to 7 
days following a TAVI procedure [3]. With these standardized criteria, 
Thongprayoon et al reported the incidence of AKI within 7 days following 
TAVI of 28% (22% in stage 1, 2% in stage 2, and 4% in stage 3) and the need 
for renal replacement therapy (RRT) during hospitalization of 3% [4]. 
Actually, compared to patients without AKI, patients who developed AKI 
after TAVI had a higher mortality rate of 9-44% at 30 days and 32-56% at 1 
year [5] [6]. Moreover, in the meta-analysis of Elhmidi et al, a higher 
preoperative SCr concentration, blood transfusion and peripheral vascular 
disease are independent predictors of AKI after TAVI [6]. The association 
between AKI and higher (four-fold) postoperative mortality following TAVI, 
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was independent of baseline risk profile characteristics and peri-procedural 
complications [7], suggesting that AKI is a marker for multiorgan failure and 
is therefore associated with a higher mortality rate. The mechanisms of the 
growth in morbidity and mortality are: (1) fluid retention with AKI, (2) 
metabolic acidosis and cardiac dysfunction, and (3) arrhythmia caused by 
electrolyte imbalance.  
Despite their potential to induce acute tubular necrosis, the impact of CA 
utilization on AKI after TAVI remains controversial. A few studies suggest 
an association between CA amount and higher AKI incidence following TAVI 
[8] [9], especially in patients with pre-existing CKD [10], but a recent meta-
analysis has shown just a trend toward major CA received in AKI patients [2]. 
However, another meta-analysis [11] as well as other reports have not 
demonstrated such association [7] [12] [13] [14] [15] [16]. Minimization of 
the contrast dose during TAVI to < 100 mL and use of IOCA or LOCAs can 
explain these observations [8] [13] [17] [18].  
Yamamoto et al assessed that the ratio of CA volume x serum creatinine 
(SCr)/body weight (BW) > 2.7 and CA volume/creatinine clearance (CCr) > 
3.7 for predicting AKI could be considered threshold values to decrease the 
risk of AKI during TAVI [8]. However, for increased levels of SCr, estimated 
Glomerular Filtration Rate (eGFR) must be approximately 50% decreased. 
Thus, by the Cockroft-Gault formula, CCr might be calculated higher than it 
should be; the accuracy of eGFR calculation is higher for impaired or normal 
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kidneys. For the evaluation of contrast induced AKI development, the CA 
volume/eGFR ratio can be assumed as a more reliable parameter than the CA 
volume/CCr. According to Gul et al, the CA volume/eGFR ratio which may 
predict the development of contrast induced AKI was determined as 3.9 (AUC 
0.773, 95% CI 0.604–0.906, sensitivity 71%, specificity 80%) [19]. 
Hyperosmolality of CA may play a role in the pathogenesis of contrast-
induced AKI by causing relatively greater degrees of intra-renal 
vasoconstriction, activating tubuloglomerular feedback, or increasing tubular 
hydrostatic pressure, all of which could result in decreased GFR and 
worsening medullary hypoxemia [20] [21] [22]. A common assumption in 
many trials has been that, in keeping with the NEPHRIC study [23], iodixanol 
is a safer agent, at least in those at higher risk of contrast induced AKI, such 
as those with CKD due to diabetes mellitus. Such iso-osmolal contrast agent 
(IOCA) was demonstrated to be associated with less nephrotoxicity compared 
with higher osmolal CAs commonly in use [24]. Notwithstanding the findings 
of Biondi-Zoccai et al. suggest that there is no difference between iodixanol 
and low-osmolal contrast agents (LOCAs) like iomeprol, iopamidol and 
ioversol, being associated with similar absolute risks of contrast induced AKI 
or ≥ 25% increase of in SCr, and also having comparative odds ratios. [25]. 
Focusing the effect of contrast osmolality in TAVI cohorts, two studies had 
shown that the type of CA, IOCA or LOCA, had no influence on the 
occurrence of AKI [8] [26]. 
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In this observational retrospective study, we compared the incidence of AKI 
after TAVI in patients receiving IOCA vs. LOCAs. Additionally, we assessed 
the relationship between the occurrence of TAVI-induced AKI and short-term 
mortality, and investigated predictors for the occurrence of AKI following 
TAVI, particularly trying to define new predictive threshold values of the 
three ratios involving CA volume administered. 
MATERIALS AND METHODS 
Study population 
Between March 2011 and July 2016, a total of 459 consecutive patients 
diagnosed with symptomatic severe AS underwent TAVI at the 
“Montevergine” Clinic (115 patients, three operators), Mercogliano, Italy, at 
the “Santa Maria” Clinic (299 patients, two operators), Bari, Italy, and at the 
Policlinico University Hospital (45 patients, one operator), Bari, Italy. Patients 
in chronic hemodialysis treatment as well as patients who died within the 72 
hours precluding SCr measurements following TAVI were excluded from the 
study. Patients who received iodinated CAs within 5 days prior and 72 hours 
after TAVI, e.g. for Computed Tomography (CT), angiography, Percutaneous 
Coronary Intervention (PCI), were excluded from the analysis too, thus the 
final study population consisted of 412 patients. 
Details on the TAVI procedure are provided elsewhere [27]. The following 
devices were used for implantation: SAPIEN XT and SAPIEN 3 (Edwards 
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Lifesciences, Irvine, CA, USA), CoreValve®, Engager® and CoreValve® 
Evolute R™ (Medtronic Inc., Minneapolis, MN, USA), JenaValve 
(JenaValve, Munich, Germany), Acurate and Acurate Neo (Symetis, 
Ecublens, Switzerland), and finally Direct Flow Medical (Direct Flow 
Medical® Inc., Santa Rosa, CA, USA). 
In diabetic patients on metformin treatment, this drug was suspended 48 hours 
before TAVI. All patients had an overnight hydration before the procedure: 1 
mL/kg/h of 0.9% NaCl solution for 24 hours, at a rate of 60 to 100 mL/hour 
(according to the individual left ventricular function, pulmonary artery 
pressure, and combined valvular disease), beginning 12 hours before the 
scheduled procedure); such isotonic saline solution was implemented for 24 
hours before TAVI to the patients with eGFR < 50 mL/min/1.73 m2. 
The number of rapid pacing runs, the occurrence of any complication leading 
to severe maintained hypotension, and/or the need for hemodynamic support 
(aortic counterpulsation balloon and extracorporeal circulation) were 
recorded. Periprocedural events and device success were defined according to 
the VARC-2 standardized criteria [28]. Follow-up at 30 days was carried out 
by clinical outpatient visits. Re-hospitalizations for all causes and heart failure 
were recorded during the follow-up period. Physicians responsible for the 
patients were contacted and/or medical charts were reviewed to determine the 
causes of re-hospitalization and/or death when necessary. 
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All clinical, echocardiographic, procedural, and post-procedural data were 
prospectively gathered through dedicated archiving software used by each 
center. The study protocol was in accordance with the institutional ethics 
committee of each participating center as well as the Declaration of Helsinki, 
and all patients gave informed written consent for the procedures.  
CAs assessment 
The CAs used for the procedure were: (1) iodixanol (Visipaque™®, GE 
healthcare, Little Chalfont, United Kingdom), iodinated non-ionic iso-
osmolality, dimeric, (2) iopromide (Ultravist™®, Bayer Healthcare, Berlin, 
Germany), (3) iobitridol (Xenetix™®, Guerbet, Villepinte, France), (4) 
iohexol (Omnipaque™®, GE healthcare, Little Chalfont, United Kingdom) 
and (5) iomeprol (Iomeron™®, Bracco Imaging, Konstanz, Germany), all 
iodinated non-ionic low-osmolality, monomeric. According to osmolality of 
the different CAs, the population was divided in 2 groups: IOCA group (n = 
230) (iodixanol 320: 290 mosmol/kg H2O) and LOCA group (n = 182) 
(iopromide 300-370: 590-770 mosmol/kg H2O; iobitridol 350: 915 
mosmol/kg H2O; iohexol 350: 780 mosmol/kg H2O; iomeprol 350: 618 
mosmol/kg H2O). 
According to the previous investigations, the CA volume x SCr/BW, CA 
volume/CCr and CA volume/eGFR ratios were used to evaluate the degree of 
CA dose in individual patients [8] [19]. 
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The cumulative CA exposure for preoperative CT scan, catheterization, and 
TAVI has not been taken into account because the time interval to TAVI was 
more than 5 days for all patients enrolled. 
Assessment of renal function and AKI definition 
SCr level was measured at baseline (1 day before the procedure), on the 
procedure day (after continuing the overnight hydration), and then daily until 
the discharge. SCr concentrations before TAVI were available in all patients. 
If there was > 1 measurement post-TAVI available, the greater SCr value 
within 48 hours was included in the analysis. Patients were monitored for at 
least 72 hours for urine output. 
eGFR was calculated with the simplified Modification of Diet in Renal 
Disease (MDRD) formula [29], while CCr rate using Cockcroft-Gault 
formula. For the present analysis, CKD was defined as baseline eGFR of < 60 
mL/min/1.73 m2. 
AKI was defined as stage 1, 2, or 3 according to VARC-2 [28] following 
Acute Kidney Injury Network (AKIN) classification [30]. Patients receiving 
RRT were considered to meet stage 3 criteria irrespective of other criteria. The 
indications for RRT included fluid overload with heart failure, hyperkalemia, 
hypercalcemia, metabolic acidosis, uremic symptoms, and oliguria or anuria 
(urine output < 200 mL/12 hours or urine output < 50 mL/12 hours, 
respectively). 
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Risk factors and endpoints 
Preoperative risk-related variables were defined according to the EuroSCORE 
definitions and outcomes were reported according to VARC-2 definitions 
[28]. Primary study endpoints is to investigate the relationship between 
contrast agent osmolality and the occurrence of any change in renal function 
or any grade of periprocedural AKI during TAVI, as well as to identify 
potential new AKI predictors or to confirm those already mentioned in the 
literature. 
Secondary endpoints to identify potential new AKI predictors or to confirm 
those already mentioned in the literature. 
Tertiary endpoints are: all-cause mortality, cardiac death, stroke, myocardial 
infarction, cumulative major adverse cardiac events (MACE) at 30 days, 
cumulative early safety and procedural success [28], congestive heart failure 
requiring hospital re-admission, but also intravalvular and paravalvular aortic 
regurgitation, and prosthetic valve dysfunction, evaluated according to the 
integrative approach outlined in the algorithm advocated by current guidelines 
[31]. 
Statistical analysis 
Statistical analyses were performed using SPSS 16.0. Variables were 
expressed as absolute numbers and percentage or mean ± SD. Comparisons 
were made by t-test, χ2 test or z-test as appropriate. 
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Univariate and multivariate logistic regression analysis were performed to 
identify independent predictors of AKI development. All statistical tests were 
two-sided. For all tests, a p-value < 0.05 was considered statistically 
significant. 
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PRELIMINARY RESULTS 
Baseline characteristics of the study population (n=412). 
 
 Number Percentage or mean (SD) 
Age (yrs)  80.7 (5.8) 
Male 188 45.6 
Body Mass Index (kg/m2)  27.6 (4.8) 
Hypertension 376 91.3 
Diabetes mellitus 142 34.5 
Dyslipidemia 210 51.0 
Smoking 17 4.1 
Chronic kidney disease (eGFR < 60 
ml/min/1.73m2) 175 42.5 
eGFR (ml/min/1.73m2)  67.8 (26.3) 
Anemia 217 52.7 
COPD 134 32.5 
Neurological dysfunction 37 9.0 
Severe liver disease 17 4.1 
PAD 102 24.8 
Porcelain aorta 13 3.2 
Critical preoperative state 30 7.3 
PM/ICD/CRT implantation 42 10.2 
Previous MI 69 16.7 
Previous cardiac surgery 70 17.0 
Previous myocardial revascularization 108 26.2 
PCI 55 13.3 
CABG 28 6.8 
PCI+CABG 25 6.0 
Myocardial revascularization for TAVI 60 14.6 
PCI 57 13.8 
CABG 2 0.5 
PCI+CABG 1 0.2 
Coronary artery disease (≥50%) during TAVI 61 14.8 
Bridge valvuloplasty 8 1.9 
NYHA functional class III-IV 363 88.1 
Logistic EuroSCORE  17.67 (13.84) 
STS score (mortality)  5.41 (4.33) 
 
Echocardiography   
LVEF (%)  53.6 (12.0) 
Maximum aortic gradient (mmHg)  76.2 (21.7) 
Mean aortic gradient (mmHg)  47.1 (14.4) 
Indexed aortic valve area (cm2/m2)  0.39 (0.18) 
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SD = standard deviation; PPMI = permanent pacemaker implantation; COPD 
= chronic obstructive pulmonary disease; PAD = peripheral artery disease; 
PM = pacemaker; ICD = implantable cardioverter-defibrillator; CRT = cardiac 
resynchronization therapy; MI = myocardial infarction; PCI = percutaneous 
coronary intervention; CABG = coronary artery bypass grafting; TAVI = 
transcatheter aortic valve implantation; NYHA = New York Heart 
Association; STS = Society of Thoracic Surgery; LVEF = left ventricular 
ejection fraction. 
  
Moderate to severe mitral regurgitation 180 43.7 
Pulmonary arterial systolic pressure 
(mmHg)  39.6 (13.3) 
 
Electrocardiography    
Heart rhythm   
Sinus rhythm 319 77.4 
History of paroxysmal atrial 
fibrillation  48 11.6 
Atrial fibrillation / flutter 66 16.0 
PM-induced rhythm 27 6.6 
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Procedural features and outcomes (n=412). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Number 
Percentage or  
mean (SD) 
CT-guided procedure 389 94.4 
   
Vascular access route   
Transfemoral 371 90.0 
Transapical 35 8.5 
Transaortic 6 1.5 
   
Valve-in-valve 9 2.2 
Predilation valvuloplasty 298 72.3 
Postdilation 39 9.5 
Contrast used (ml)  177.6 (68.2) 
Device success 354 85.9 
Hospital length of stay (days)  5.7 (5.1) 
   
Any complication (VARC-2) 171 41.5 
PPMI 41 10.0 
Access site-related complic. 65 15.8 
Vascular complications 70 17.0 
Minor 57 13.8 
Major 13 3.2 
PCD failure 34 8.3 
Bleeding 84 20.4 
Minor bleeding 33 8.0 
Major bleeding 45 10.9 
Life-threatening bleeding 6 1.5 
Need of transfusion 44 10.7 
1 unit 24 5.8 
2 units 17 4.1 
>2 units 3 0.7 
Residual AR ≥ moderate 32 7.8 
Myocardial infarction 3 0.7 
New-onset LBBB 97 23.5 
New-onset AF/flutter 35 8.5 
Any AKI 39 9.5 
AKI 1 29 7.0 
AKI 2 7 1.7 
AKI 3 3 0.7 
Haemodialysis 4 1.0 
Chronic hemodialysis 1 0.2 
Stroke 4 1.0 
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SD = standard deviation; PPMI = permanent pacemaker implantation; PCD = 
percutaneous closure device; AR = aortic regurgitation; AF = atrial 
fibrillation; LBBB = left bundle branch block; AKI = acute kidney injury. 
 
Patients characteristics by groups. 
VARIABLE IOCA group  
 
LOCA group 
 
p 
Patients (n: 412) 230 182  
Age (yrs) 80,45 ± 5,78 80,94 ± 5,91 0,396 
Diabetes % (n) 35,65 (82) 32,97 (60) 0,642 
Arterial Hypertension % 87,83 (202) 95,60 (174) 0,009 
Euroscore II (n) 10,51 ± 51,36 6,86 ± 7,25 0,356 
STS Score (n) 3,94 (2,74-
6,39) 
4,32 (3,25-6,55) 0,064 
AKI (n)  7,83 (18) 11,54 (21) 0,268 
ΔeGFR ml/min (post-pre 
TAVI) 
3,78 ± 17,27 -3,09 ± 14,87 0,002 
ΔeGFR ml/min (1 week) 6,41 ± 19,45 1,10 ± 13,92 0,002 
Transfusions (n) 0,14 ± 0,53 0,22 ± 0,69 0,178 
PAD (n) 35,22 (81) 27,47 (50) 0,116 
Ratio 1 (vol x sCR/w) 2,97 ± 1,5 2,48 ± 1,4 <0,001 
CKD pre-TAVI 42,61 (98) 42,31 (77) 0,969 
Iodio ratio (mg) 935,97 ± 
481,74 
803,12 ± 557,87 0,010 
 
  
Periprocedural death 7 1.7 
30-day mortality 15 3.6 
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Post-TAVI AKI predictors. 
 Univariate p value 
Multivariate 
p value 
CA kind 0,169  
Isosmolality 0,204 0,057 
CA volume 0,358  
Diabetes 0,582  
Transfusions (n) <0,001 0,090 
PAD 0,100  
Ratio 1 (vol x sCR/w) <0,001 0,085 
CKD 0,031  
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PART 2 
 
Peripheral arterial disease 
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CHAPTER 8 
Combined use of directional atherectomy and drug coated 
balloon for the endovascular treatment of common femoral 
artery disease: immediate and one-year outcomes 
Aims. Surgical endarterectomy is the therapy of choice for atherosclerotic 
common femoral artery (CFA) obstruction. Recently, some large single-centre 
series have shown encouraging results for the percutaneous treatment of CFA 
obstructions. The purpose of this study was to evaluate the safety, feasibility, 
and one-year efficacy of the endovascular treatment of CFA obstructions with 
combined use of directional atherectomy (DA) and a paclitaxel-coated balloon 
(DCB). 
Methods and Results. Between January 2012 and July 2014, 30 consecutive 
patients with severely calcified obstructions of the common femoral artery 
were treated in our centre using DA followed by DCB dilatation. Provisional 
stenting was allowed in the case of a suboptimal result. Twenty cases (66%) 
were isolated CFA interventions, whereas five (17%) and five (17%) also 
involved inflow and outflow vessels, respectively. Chronic total CFA 
occlusions (CTO) were recanalised in six cases (20%). Procedural success was 
achieved in all cases; stenting was needed in three cases (10%). At one year, 
restenosis and target lesion revascularisation were observed in two of 30 
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(6.6%) and one of 30 (3.3%) patients, respectively. The secondary patency 
rate was 96.7%. 
Conclusions. This single-centre prospective study suggests that the combined 
use of DA and DCB is a safe and effective alternative to surgery, a treatment 
option for common femoral artery lesions and provides encouraging results in 
this setting. 
 
Treatment of complex common femoral artery obstruction using directional 
atherectomy and drug-coated balloon. (a) Selective angiography showing a calcific 
obstruction of the distal CFA involving the ostium of both the superficial femoral 
artery (SFA) and the profunda femoral artery (PFA). (b) Use of directional 
atherectomy to debulk the segment CFA-SFA. (c) Use of directional atherectomy to 
debulk the segment CFA-PFA. (d) Selective angiography showing optimal plaque 
removal after directional atherectomy. (e) Simultaneous drug-coated balloon dilation. 
(f) Selective angiography showing final result.  
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CHAPTER 9 
Incidence and predictors of acute kidney injury in patients 
undergoing to proximal protected carotid artery stenting 
Aims. Many studies have analysed the occurrence of acute kidney injury (AKI) 
after percutaneous coronary intervention (PCI) but there are limited data 
relating to AKI risk in patients undergoing carotid artery stenting (CAS). The 
aim of this study was to determine the incidence and predictors of AKI in 
patients undergoing proximal protected CAS. 
Methods and Results. We analysed 456 patients undergoing proximal 
protected CAS. A binomial multivariate logistic model was developed 
including patients’ clinical and angiographic/procedural characteristics. AKI 
(defined as an sCr increase ≥ 0.3 mg/dl or ≥ 1.5-fold sCr increase from 
baseline or more than 50% increase from baseline, within 48 hours post 
procedure) occurred in 155 patients (34%). AKI patients were more frequently 
affected by hypertension, diabetes, dyslipidaemia and anaemia, and presented 
lower renal function at baseline. Higher contrast volume to creatinine 
clearance ratio (2.40 ± 1.44 vs. 2.08 ± 1.15; p = 0.01), lower post-procedural 
mean arterial pressure (MAP) (94.3 ± 17.7 vs. 99.6 ± 18.5 mmHg; p = 0.003) 
and a more frequent post-procedural systolic pressure drop (ΔSBP >50 
mmHg) (23.9% vs. 14.3%, p = 0.01) were observed in the AKI group of 
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patients. At multivariate analysis, independent predictors of AKI were ΔSBP 
> 50 mmHg, diabetes mellitus and dyslipidaemia. 
Conclusions. AKI can occur quite frequently after proximal protected CAS 
and is related to clinical and procedural features. These data should be 
confirmed in larger registries or randomised trials. 
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PART 3 
 
Coronary arteries and their diseases 
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CHAPTER 10 
A striking coronary artery pattern in a grown-up congenital 
heart disease patient 
Left ventricular non-compaction (LVNC) is a myocardial disorder, which is 
thought to occur due to the arrest of normal embryogenesis of the left ventricle 
(LV), leading to distinct morphological characteristics in the ventricular 
chamber. The affected segments had a two layer structure: a compact 
epicardial layer and an endocardial layer consisting of a prominent trabecular 
meshwork and deep intertrabecular spaces; these features are found 
predominantly in the apical and the mid ventricular segments of the LV. 
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It is classified in isolated NC and in ventricular NC associated with other 
extracardiac and cardiac abnormalities, including coronary artery anomalies.  
 
The prevalence varies considerably among different series and is still 
unknown; several limitations for this assessment are the different diagnostic 
criteria, the heterogeneous populations, and the retrospective design of most 
studies. Because of continuous improvement of imaging resolution quality, 
this cardiomyopathy is increasingly diagnosed, also if it remains frequently 
misdiagnosed especially in the cases of LVNC associated with other heart 
defects. Clinical signs are variable, ranging from lack of symptoms to heart 
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failure, thromboembolic events, arrhythmias till sudden cardiac death, also if 
the pathophysiologic mechanisms of these severe manifestations in LVNC are 
partially unclear.  
We have presented a case of LVNC association with both malposition of the 
great arteries and a very original coronary pattern. 
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CHAPTER 11 
How to approach a spontaneous coronary artery dissection: an 
up-to-date 
Spontaneous coronary artery dissection (SCAD) is a separation of the 
coronary wall layers, not related to trauma, medical procedures or 
atherosclerosis. The dissection causes the blood entry in the vascular wall with 
the consequent formation of a false lumen and intramural hematoma. Two 
pathogenetic mechanisms have been proposed to explain SCAD: a “primary” 
rupture of coronary endothelium or the rupture of the “vasa vasorum”. Clinical 
presentation and severity of manifestations are variable, ranging from 
complete absence of symptoms to acute coronary syndrome, cardiogenic 
shock, cardiac arrest or sudden cardiac death. Despite coronary angiography 
is the first-line examination, by supplying two-dimensional images of the 
lumen, it does not always allow an incontrovertible diagnosis of SCAD. New 
intravascular imaging techniques, such as optical coherence tomography and 
intravascular ultrasound, have been recently introduced and may be extremely 
helpful in assessing the coronary wall integrity, thus improving coronary 
angiography diagnostic accuracy. 
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Because of the lack of large randomized trials comparing different strategies, 
the optimal treatment of SCAD is still controversial. The first-line approach 
is conservative and based on medical therapy. Nevertheless, in particular 
situations an invasive approach is necessary. In the last years, several new 
strategies have improved the way to perform percutaneous coronary 
interventions, such as new generation drug eluting stents, bio-resorbable 
scaffolds, sirolimus self-expandable stent, drug eluting balloons, and cutting 
balloon. Cardiac artery bypass graft is an even more invasive method to 
restore coronary flow and should be considered in urgent/emergent settings 
when PCI is not feasible or has failed. 
Cause the therapeutic approach of SCAD can be substantially different from 
that of atherosclerotic coronary artery disease, an accurate diagnosis is crucial 
to set up the best treatment strategy.  
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CHAPTER 12 
A new noninvasive method for assessing mild coronary 
coronary atherosclerosis: trans-thoracic convergent color 
Doppler after heart rate reduction. Validation versus 
intracoronary ultrasound 
Background. A more sensitive transthoracic color Doppler technology 
(convergent color Doppler), along with a heart rate (HR) reduction and new 
tomographic planes, can greatly improve coronary blood flow velocity (BFV) 
recordings in the left main (LMCA) and left anterior descending (LAD) 
coronary arteries, allowing the detection of even a slight acceleration of BFV 
due to mild coronary stenosis. 
Methods. A group of 26 patients underwent CC-Doppler-TTE in the LMCA 
and in the LAD coronary arteries before and after HR lowering. A second 
group of 71 patients scheduled for intravascular ultrasound underwent BFV 
Doppler recordings by CC-Doppler-TTE of the whole LAD (specifically the 
proximal, mid and distal segments) to detect a localized increase of BFV, after 
attaining maximal and reference BFV in each segment. 
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Results. In the first group, HR reduction dramatically improved the detection 
of optimal flow in the LMCA and LAD, from 4% to 54% and from 6% to 94% 
of the segments, respectively (p < 0.001). In the second group IVUS showed 
mild stenoses in 60 patients. Maximum velocity was higher in the diseased 
segment than normal segments (49 ± 24 vs 30 ± 9 cm/s; p < 0.001) and as the 
reference velocity was similar (32 ± 9 vs 30 ± 9cm/s; p = ns), the % increase 
was also higher (52 ± 52% vs 0.5 ± 3%; p < 0.001). Using a 22% increase in 
velocity as cut-off value, the sensitivity and specificity of CC-Doppler TTE in 
detecting at least one LAD plaque were 87% (52/60 pts) and 100% (11/11 
pts), respectively. The lumen stenosis area (%), assessed by IVUS and by 
applying the CC-Doppler TTE continuity equation, was similar (35 ± 13% vs 
41 ± 14%; r = 0.55; p < 0.001). 
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Conclusion. CC-Doppler-TTE evaluation of LAD BFV is greatly improved 
after reducing HR, allowing accurate non-invasive assessment of mild LAD 
stenosis with no radiation exposure.  
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CHAPTER 13 
Establishing reference values for the diagnosis of coronary 
artery ectasia in current practice 
INTRODUCTION 
Coronary artery ectasia 
Coronary artery ectasia (CAE), originally defined as a diffuse or 
segmental dilatation of the coronary artery with a diameter of more than 
1.5 times the normal adjacent segments or the patient’s largest coronary 
artery, was first described in 1976 by Markis et al [1]. Since then, the 
diagnosis of CAE has not evolved and it remains currently based on a 
comparative assessment of coronary diameters by visual estimation in 
reference to healthy vessels. This historical definition suffers from 
multiple limitations, including the impossibility to establish the 
diagnosis in patients with diffuse CAE as well as the lack of 
reproducibility derived from the absence of objective measures. 
Therefore, the inter-observer variability may play a significant role in 
the diagnosis and prevalence discrepancies reported by different 
investigators. So far, this has caused the true burden of CAE to be 
largely underestimated in fact the absence of reference values forces 
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interventional cardiologists to diagnose CAE only in the presence of 
self-evident and full-blown cases. Moreover, as stated above the current 
working definition impedes the diagnosis in patients with diffuse CAE 
in whom no reference artery diameter exists. 
The reported prevalence varies between 0.2 and 10% in unselected 
series of patients referred for coronary artery angiography (CAG) with 
a reported 80% co-existence with obstructive coronary artery disease 
(CAD) [2]. The co-existence of CAE with coronary atherosclerosis 
raised the concept that ectasia may represent a variant of CAD [2-4] 
however a definite link between atherosclerosis and ectasia has not been 
confirmed. 
Ectactic coronary arteries and the consequent impaired coronary blood 
flow is associated with complications including delayed antegrade 
coronary filling, segmental back flow phenomenon (milking 
phenomenon) and stasis in the dilated segments which can lead to 
ischemic heart disease, thrombus formation and possible distal 
embolization. Coronary artery aneurysm rupture is the most life-
threatening complication which is associated with a significant rate of 
patient morbidity [5].  
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The clinical presentation of patients with CAE varies from 
asymptomatic to atypical chest pain, stable angina, acute coronary 
syndromes and sudden death. In those with a concomitant obstructive 
CAD, the symptoms are mostly believed to be associated with the 
severity of coexisting obstructive lesion. However, patients with 
isolated CAE may also present with stable angina, positive treadmill 
test, increased levels of biochemical markers or even myocardial 
infarction [6-7]. These observations suggest that CAE per se is a 
malignant condition, which can induce and be associated to myocardial 
ischemia and its related clinical consequences. At the same time, the 
appropriate diagnosis of CAE may help identifying these patients and 
support future studies on their optimal management. Indeed, there is no 
consensus regarding medical management of CAE (aspirin, P2Y12 
inhibitors, and anticoagulants like warfarin have all been suggested but 
poorly investigated) and invasive management of these patients poses 
great challenges during percutaneous interventions due to large burden 
of thrombus, large diameters and high risk of vessel damage and 
rupture. 
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Normal coronary diameters 
Only if the “normal” is defined we can truly determine the “abnormal”. 
Hence, the first step toward developing a more precise and practical 
definition for the CAE is to define the normal coronary artery 
diameters. Importantly, the same methodological approach has been 
followed for the thoracic or abdominal aorta reference diameters in 
order to establish the diagnosis of aneurismal conditions associated to 
its enlargement, whereas this rigorous scientific approach is currently 
missing for the coronary arteries.  
In current available body of literature, the majority of studies with the 
aim of defining normal coronary artery diameters have been conducted 
during postmortem examinations of the heart [7]. The only two studies 
which focused on this subject by Vieweg et al. [8] and Dodge et al. [9] 
patients with valvular and structural heart disease were included, 
despite the fact that such conditions are known to influence the coronary 
lumen diameters by increased myocardial flow demand [10]. Dodge et 
al. demonstrated that the lumen diameter of most arterial sub-segments 
could be specified when gender, anatomic variation, branch length, and 
specific determinants of myocardial mass are taken into account. They 
indicated that in normal men, the combination of sub-segment location, 
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anatomic distribution pattern and the branch artery length categories 
provide an estimation of normal lumen diameter with a relatively small 
population variance [9]. However, it is noticeable that the above-
mentioned studies were conducted years before the availability of the 
current advanced quantitative coronary measurement methods and as 
such they cannot form the basis for establishing the diagnosis of normal 
coronary arteries in current practice.  
The continuously expanding implementation of CAG for investigation 
of cardiovascular disease warrants an undeniable need for standard 
reference measures to define the normal coronary artery luminal size 
and subsequently establish a diagnosis of CAE. 
We have quantified the coronary artery luminal diameters in a 
rigorously selected normal healthy population in order to establish 
segment-specific, gender and body mass index normalized reference 
values for the coronary arteries. This will allow to develop reference 
thresholds for CAE diagnosis. 
The proposed research project has major implications in the field of 
cardiology. It will form the basis for establishing the segment-specific 
reference coronary artery dimensions in normal and pathologic 
conditions.  
67 
 
MATERIALS AND METHODS 
Study population 
Data of all consecutive patients between November 2014 and June 2018 
who underwent CAG at Bern University Hospital and diagnosed with 
the terms “normal coronary arteries”, “coronary aneurysm”, “coronary 
ectasia” or “coronary dilation” in their catheterization reports have been 
retrospectively collected to generate the study database. Demographic 
features, medical comorbidities and therapy at the time of the CAG as 
well as during and after index hospitalization, data concerning cardiac 
clinical events occurring after discharge have been collected by the 
available medical reports and in form of a questionnaire. 
Then a sequential two-step selection process based on the following 
inclusion and exclusion criteria have been applied. In the first step, the 
two populations of interest have been patients without any evidence of 
CAD (no quantified stenosis), labeled as the “non-stenotic population” 
(850 patients) and those with reported CAE, regardless of the presence 
or absence of concomitant CAD, which have been labeled as “ectactic 
population” (100 patients). In the second step, more stringent criteria to 
identify a normal coronary population have been employed to allocate 
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patients of the “non-stenotic population” into two the “broad sample” 
(727 subjects) and “reference sample” (123 subjects) categories. 
According to the further described inclusion and exclusion criteria, only 
9 patients belong to both the ectactic population and the broad sample. 
 
Inclusion and exclusion criteria 
“Non-stenotic” and “ectactic” populations inclusion criteria are age ≥ 
18 years; normal and/or ectatic coronary artery(ies); at least 4 available 
orthogonal angiographic projections of the left coronary artery and 2 
orthogonal projections of right coronary artery; written informed 
consent (retrospectively collected) or waiver from the ethics committee. 
The exclusion criteria are: any evidence of CAD or prior self-limiting 
spontaneous coronary artery dissection; evidence of ischemia and/or 
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myocardial injury as assessed by high sensitivity troponin, valvular (at 
least of moderate severity), structural, congenital (including coronary 
anomalies, but excluding PFO, dextrocardia and situs viscerum 
inversus), infectious (endocarditis, myocarditis, pericarditis or 
combination of them) or neoplastic heart disease; left ventricular (LV) 
dysfunction; significant LV hypertrophy; evidence of any aortic 
lesions, such as atherosclerotic, aneurysm, dissection (acute or chronic), 
genetic, infectious, inflammatory or neoplastic aortic disease; evidence 
of intra-cardiac thrombosis; history of any interventional 
cardiovascular therapies; such as coronary revascularization, valvular 
repair or replacement and structural, aortic or peripheral arterial defects 
repair; prior heart, aortic and peripheral arteries surgery; admission due 
to congestive heart failure or cardiac arrest (in- or out-of-hospital); 
established or suspected peripheral arterial disease; connective tissue 
disease; brain death (potential organ donor) and pregnancy. 
In order to further differentiate the “non-stenotic population” into its 
two sub-groups, criteria for “reference sample” are: no prior or intra-
procedural administration of long-acting intravenous or intracoronary 
nitrates; no stroke or pulmonary embolism as the final diagnosis; 
absence of resistant or uncontrolled arterial hypertension, diabetes 
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mellitus, hypercholesterolemia, obesity or active smoking habit; no 
current or prior history of atrial fibrillation or any other cardiac 
arrhythmias; absence of aortic ectasia, isolated right ventricular failure 
or primary pulmonary hypertension; absence of acquired or 
congenital/syndromic peripheral arteriovenous malformations; stable 
hemodynamic conditions; absence of chronic lung, liver, kidney or 
thyroid dysfunction or being recipient of lung, liver or kidney 
transplantation; absence of anemia, thrombocytopenia or hemolytic 
failure; absence of known malignancy; absence of any autoimmune 
disease; absence of chronic or acute (last 2 months) infectious disease; 
no alcohol/drug abuse; no treatment with steroids; no recent (<3 
months) surgery. The patients’ medical history and 
physician‑administered physical examination information, as well as 
data from biochemical and instrumental tests, such as EKG, 
transthoracic echocardiography or other imaging modalities if available 
have been obtained from the hospital’s medical records. Blood pressure 
was routinely obtained during the catheterization admission in all cases. 
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Imaging analysis 
Films have been inspected by two experienced interventional 
cardiologists. Depending on the vascularization of the inferior septum 
as well as inferior and posterior LV walls, four possible dominance 
patterns will be identified: right, “small” right, balanced and left. All 
segments and branches of the coronary artery tree have been identified, 
and the anatomy has been reduced to a set of up to 96 defined sub-
segments (96 points in 32 defined coronary segments), according to 
Dodge et al [9]. In accordance to this methodology, terminal branches 
(diagonals, marginals, median ramus, etc.) have been classified by size 
into one of five groups: long, medium, short, absent, or unseen. This 
branch size rating refers to the vessel's length of distribution, not its 
width per se; where these vessels branched, their longest extension will 
be used. 
Abbreviation Name Description 
Main arteries 
LCA Left coronary artery 
LM Left main 
LAD Left anterior descending 
LCx Left circumflex 
RCA Right coronary artery 
Main artery segments 
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C1 LCx first 
segment 
LCx from its origin at the LM to M1 (or 
OM, if M1 is absent) 
C2 LCx second 
segment 
LCx from Ml to M2 (or OM) (not present if 
Ml is absent) 
C3 LCx third 
segment 
LCx from M2 (or OM) to CP (if present, 
otherwise to end of LCx) 
C4 LCx fourth 
segment 
LCx from CP along atrioventricular groove 
to end of LCx (absent in RCA and small-
RCA dominant distributions) 
L1 LAD first 
segment 
LAD from its origin at the LM to I septal 
branch (S1) 
L2 LAD second 
segment 
LAD from S1 to S3 
L3 LAD third 
segment 
LAD from S3 to the cardiac apex 
L4 LAD fourth 
segment 
LAD from the cardiac apex to its terminal 
point on the inferior wall 
LM Left main LCA from ostium to bifurcation of LCA 
into LAD and LCx 
R1 RCA first 
segment 
RCA from its origin to I acute marginal 
branch (Al) 
R2 RCA second 
segment 
RCA from Al to A3 
R3 RCA third 
segment 
RCA from A3 to RD (if present, otherwise 
to end of RCA) 
R4 RCA fourth 
segment 
RCA from the RD along atrioventricular 
groove to end of RCA (absent in balanced 
and LCA dominant distributions) 
Branch artery segments 
CD Posterior 
descending 
Distal most inferior wall branch arises from 
C4, present only in left-dominant anatomy 
CI Inferior Inferior wall branch arises from C4 (present 
only in balanced and LCA dominant 
anatomy) 
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CP Posterior Proximal most inferior wall branch arises 
from junction of C3 and C4 (present in 
small-right, balanced, and LCA dominant 
anatomy) 
D1-D3 Diagonals Three largest branches arising from the 
LAD to supply the left ventricular anterior 
free wall, numbered from most proximal to 
most distal 
M1-M3 Marginals Three largest branches arising from the 
LCx to supply the left ventricular lateral 
free wall, numbered from most proximal to 
most distal 
MR Median 
ramus 
An anatomic variant arising at a trifurcation 
of the LM 
OA Anterior 
branch OM 
Anterior distal branch of OM 
OM Obtuse 
marginal 
Anatomic variant present when one branch 
artery off the LCx is much larger than its 
neighbors supplying the left ventricular 
lateral free wall 
OP Posterior 
branch OM 
Posterior distal branch of OM 
RD Posterior 
descending 
Proximal most inferior wall branch arises 
from junction of R3 and R4 (present in 
right, small-right, and balanced dominant 
anatomy) 
RI Inferior Inferior wall branch arises from R4 (present 
only in right and small-right dominant 
anatomy) 
RP Posterior Distal most inferior wall branch arises from 
R4 (present only in right dominant 
anatomy) 
The vessel diameters have been analyzed using a computerized 
bidimensional and tridimensional QCA analysis system (QAngio 7.3 
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and QAngio XA 3D, Medis medical imaging systems bv, Leiden, The 
Netherlands), which represents the latest technology available for QCA 
measures. 
Statistical considerations 
When data are neither gaussian or log-gaussian, and/or an incorrect 
distribution of the data is assumed, nonparametric estimates are 
preferable and more reliable. When neither assumption is true, 
nonparametric estimates hold. Among the several nonparametric 
estimates, with the aim to determine the normal range based on the 
QCA images of the “non-stenotic population”, we have employed the 
percentile estimates together with nonparametric confidence intervals 
for the true percentile. The least sample size, which permits 90% 
confidence intervals for the normal limits, is 120 subjects. On this basis, 
n = 120 is the minimum number of samples needed for the reference 
sample to calculate normal range estimates. Utilizing this method, we 
have classified values of each angiographic variable into the following 
five categories based on sex- and BMI-specific percentiles (indicating 
increasing deviation from the reference limits): category 0 (reference 
limits): value ≤ 95th percentile of the reference sample; category 1 
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(trivial CAE): 95th percentile of reference sample < value ≤ 95th 
percentile of broad sample; category 2 (mild CAE): 95th percentile of 
broad sample < value ≤ 98th percentile of broad sample; category 3 
(moderate CAE): 98th percentile of broad sample < value ≤ 99th 
percentile of broad sample; category 4 (severe CAE): value > 99th 
percentile of broad sample 
Statistical analyses have been performed with SPSS version 25.0 and 
Stata 14.0. Continuous variables have been summarized as mean ± 
standard deviation or median ± 95% confidence interval, depending on 
normality of distribution. Categorical variables have been expressed as 
frequencies and percentages. Comparisons between continuous data 
have been performed using unpaired t-test and Wilcoxon test (or Mann–
Whitney U test when appropriate), depending on normality of 
distribution. Normality will be assessed using Kolmogorow-Smirnow 
test. Comparisons between categorical data heve been performed using 
Chi-squares test (or Fisher exact test when appropriate). Statistical 
significance threshold has been set at a p-value <0.05. 
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Good Clinical Practice (GCP) Statement 
This study has been conducted in accordance with the protocol, the 
Declaration of Helsinki, the principles of Good Clinical Practice (GCP), 
the Human Research Act (HRA) and the Human Research Ordinance 
(HRO) as well as other locally relevant regulations. 
Flowchart of the study 
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PRELIMINARY RESULTS 
Reference sample: segments length comparison between 2D and 3D 
evaluation. 
Segments n 2D mean (SD) 
(mm) 
n 3D mean (SD) 
(mm) 
p (paired t-
test) 
LM 113 9.66 (3.84) 96 11.8 (4.62) 7,98E-10 
L1 123 22.4 (9.35) 116 24.5 (11.3) 0,00338 
L2 123 37.4 (12.5) 115 40.8 (13.9) 2,63E-07 
L3 122 59.8 (12.9) 111 69.5 (14.3) 8,39E-18 
L4 95 29.7 (11.4) 64 33.4 (11.4) 0,00153 
D1 112 55.9 (21.8) 68 65.9 (25.2) 6,74E-05 
D2 85 44.8 (19.5) 59 52.7 (23.2) 1,14E-05 
D3 34 31.6 (14.7) 21 36.2 (18.3) 0,233 
MR 52 59.6 (23.2) 40 72.7 (29) 0,00278 
C1 123 20.4 (12.5) 117 22.9 (13.1) 7,66E-10 
C2 115 24.1 (11.8) 104 29.1 (14) 2,14E-10 
C3 88 24.7 (11.9) 68 26.8 (13.8) 0,00945 
C4 31 18.9 (12.4) 17 23.1 (14) 0,0655 
OM 79 48.7 (28) 75 55.7 (32.8) 0,000521 
OA 42 50.3 (22.5) 36 52.2 (18.9) 0,0663 
OP 42 45 (21.8) 37 49.5 (19.2) 0,00191 
M1 63 48 (21.6) 36 61.7 (18.6) 0,0169 
M2 72 39.6 (20.1) 41 47 (23.3) 0,0988 
M3 28 37 (21.4) 17 49.1 (24.7) 0,0536 
CP 53 40.7 (20.5) 33 44.3 (18.3) 0,387 
CI 31 32.7 (16.4) 14 38.3 (21.3) 0,306 
CD 9 38.3 (11.3) 3 36.8 (5.98) 0,655 
R1 123 25.7 (10.8) 104 28.1 (11.1) 0,000594 
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R2 123 29.1 (11.3) 104 31.6 (12.8) 1,53E-06 
R3 122 43.5 (15.4) 93 49.3 (16.2) 3,51E-08 
R4 92 32.9 (18.1) 60 36 (18.9) 0,0436 
RD 114 57.9 (18.5) 64 63.1 (16.8) 0,000404 
RI 92 41.4 (19.5) 33 42.8 (16.9) 0,819 
RP 69 47.1 (23) 27 52 (26.2) 0,477 
Reference sample: scatterplot showing BSA-indexed L1 (proximal LAD) 
diameters variation according to 2D (n = 123) or 3D (n = 116) evaluation. 
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Reference sample: point plot showing BSA-indexed L1 (proximal LAD) 
diameters variation according to 2D or 3D evaluation; p = 0,197. 
 
Reference sample: variations of main segments 2D non-indexed 
diameters according to Dodge dominance in males. 
Main 
segments 
right small right balanced left p 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
LM 
34 
4.38 
(0.724) 9 
4.41 
(0.759) 10 
5.35 
(0.71) 5 
4.61 
(0.658) 0.0112 
L1 
35 
3.64 
(0.77) 12 
3.91 
(0.583) 11 
4.06 
(0.468) 6 
3.68 
(0.491) 0.177 
L2 
35 
2.81 
(0.549) 12 
3.11 
(0.509) 11 
2.96 
(0.28) 6 
2.85 
(0.436) 0.296 
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L3 
35 
1.92 
(0.429) 12 
2.16 
(0.398) 11 
2.22 
(0.343) 6 
2.25 
(0.463) 0.0715 
L4 
27 
1.24 
(0.414) 9 
1.38 
(0.354) 10 
1.33 
(0.141) 6 
1.55 
(0.265) 0.166 
C1 
35 
3.07 
(0.753) 12 
3.63 
(0.408) 11 
4.35 
(0.951) 6 
3.84 
(0.66) 0.000103 
C2 
31 
2.23 
(0.761) 12 
2.84 
(0.82) 11 
3.29 
(0.66) 6 
3.35 
(0.686) 0.000431 
C3 
16 
1.4 
(0.491) 12 
1.99 
(0.415) 11 
2.7 
(0.805) 6 
2.45 
(0.37) 1.51e-05 
C4 
0 
NaN 
(NA) 0 
NaN 
(NA) 11 
2.01 
(0.65) 6 
1.89 
(0.412) NaN 
R1 
35 
4.14 
(0.685) 12 
4.06 
(0.268) 11 
3.64 
(0.697) 6 
2.88 
(0.269) 0.000373 
R2 
35 
3.96 
(0.683) 12 
3.76 
(0.321) 11 
3.01 
(0.822) 6 
2.13 
(0.411) 3.04e-05 
R3 
35 
3.49 
(0.561) 12 
3.24 
(0.446) 10 
2.51 
(0.815) 6 
1.25 
(0.311) 1.18e-05 
R4 
35 
2.49 
(0.469) 12 
2.2 
(0.404) 0 
NaN 
(NA) 0 
NaN 
(NA) NaN 
Reference sample: variations of main segments 2D non-indexed 
diameters according to Dodge dominance in females. 
Main 
segments 
right small right balanced left p 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
n mean (SD) 
LM 
33 
4.04 
(0.648) 10 
3.88 
(0.437) 10 
4.05 
(0.389) 2 
4.51 
(0.676) 0.547 
L1 
34 
3.59 
(0.565) 11 
3.16 
(0.591) 11 
3.22 
(0.607) 3 
2.94 
(0.515) 0.0407 
L2 
34 
2.71 
(0.579) 11 
2.36 
(0.423) 11 
2.48 
(0.64) 3 
2.35 
(0.0337) 0.216 
L3 
34 
1.69 
(0.38) 10 
1.63 
(0.362) 11 
1.69 
(0.509) 3 1.9 (0.13) 0.722 
L4 
23 
1.15 
(0.26) 8 
1.08 
(0.259) 9 
1.12 
(0.241) 3 
1.18 
(0.153) 0.794 
C1 
34 
2.97 
(0.62) 11 
2.76 
(0.43) 11 
3.36 
(0.814) 3 
3.67 
(0.326) 0.0358 
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C2 
31 
2.13 
(0.765) 10 
2.22 
(0.537) 11 
2.84 
(0.493) 3 
3.11 
(0.206) 0.00711 
C3 
19 
1.46 
(0.741) 10 
1.54 
(0.382) 11 
2.39 
(0.514) 3 2.6 (0.18) 0.000422 
C4 
0 
NaN 
(NA) 0 
NaN 
(NA) 11 
1.75 
(0.461) 3 
2.06 
(0.175) NaN 
R1 
34 
3.71 
(0.563) 11 3.4 (0.46) 11 
3.08 
(0.386) 3 
2.25 
(0.241) 0.000266 
R2 
34 
3.54 
(0.658) 11 
3.09 
(0.422) 11 
2.78 
(0.403) 3 
1.93 
(0.164) 0.00011 
R3 
34 
3.21 
(0.63) 11 
2.74 
(0.304) 11 
2.26 
(0.477) 3 
1.27 
(0.128) 4.98e-06 
R4 
34 
2.41 
(0.558) 11 
1.63 
(0.34) 0 
NaN 
(NA) 0 NaN (NA) NaN 
Reference sample: variations of main segments 3D non-indexed 
diameters according to Dodge dominance in males. 
Main 
segments 
right small right balanced left p 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
LM 
29 
4.2 
(0.636) 8 
4.19 
(0.715) 7 
4.77 
(0.649) 4 
4.69 
(0.528) 0.144 
L1 
33 
3.55 
(0.623) 11 
3.69 
(0.518) 11 
3.8 
(0.525) 6 
3.58 
(0.372) 0.588 
L2 
31 
2.71 
(0.338) 11 
2.97 
(0.454) 11 
2.83 
(0.257) 6 
2.78 
(0.357) 0.239 
L3 
32 
1.84 
(0.339) 10 
2.2 
(0.429) 9 
2.1 
(0.273) 5 
2.18 
(0.416) 0.0529 
L4 
17 
1.19 
(0.282) 6 
1.41 
(0.333) 5 
1.32 
(0.186) 4 
1.38 
(0.262) 0.39 
C1 
32 
2.85 
(0.592) 11 
3.48 
(0.433) 10 4 (0.697) 6 
3.82 
(0.651) 2.48e-05 
C2 
25 
2.22 
(0.543) 11 
2.66 
(0.822) 10 
3.07 
(0.395) 6 
3.21 
(0.754) 0.000364 
C3 
11 
1.46 
(0.469) 9 
1.84 
(0.509) 10 
2.31 
(0.661) 5 
2.53 
(0.624) 0.00309 
C4 
0 
NaN 
(NA) 0 
NaN 
(NA) 6 
1.98 
(0.663) 3 2 (0.264) NaN 
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R1 
29 
4.05 
(0.599) 11 
3.95 
(0.381) 11 
3.38 
(0.511) 5 
2.68 
(0.249) 0.000127 
R2 
30 
3.78 
(0.544) 10 
3.6 
(0.485) 10 
2.89 
(0.636) 5 
1.94 
(0.281) 3.24e-05 
R3 
26 
3.22 
(0.465) 10 
3.01 
(0.327) 9 
2.34 
(0.618) 5 
1.15 
(0.189) 1.4e-05 
R4 
25 
2.29 
(0.444) 8 
1.95 
(0.445) 0 
NaN 
(NA) 0 
NaN 
(NA) NaN 
Reference sample: variations of main segments 3D non-indexed 
diameters according to Dodge dominance in females. 
Main 
segments 
right small right balanced left p 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
n mean (SD) 
LM 
28 
3.94 
(0.417) 9 
3.86 
(0.424) 10 
4.16 
(0.358) 1 3.96 (NA) 0.457 
L1 
33 
3.43 
(0.425) 9 
3.18 
(0.518) 10 
3.33 
(0.256) 3 
2.94 
(0.553) 0.252 
L2 
34 
2.58 
(0.454) 9 
2.37 
(0.36) 10 
2.57 
(0.327) 3 
2.23 
(0.0876) 0.268 
L3 
33 
1.65 
(0.342) 9 
1.64 
(0.269) 10 
1.78 
(0.24) 3 1.8 (0.147) 0.512 
L4 
18 
1.09 
(0.255) 6 
1.17 
(0.287) 7 
1.13 
(0.144) 1 1.18 (NA) 0.943 
C1 
34 
2.9 
(0.496) 10 
2.73 
(0.469) 11 
3.33 
(0.568) 3 
3.72 
(0.176) 0.00716 
C2 
29 
2.07 
(0.624) 10 
2.19 
(0.543) 10 
2.75 
(0.394) 3 
3.01 
(0.331) 0.00465 
C3 
13 
1.48 
(0.573) 8 
1.46 
(0.337) 9 
2.4 
(0.432) 3 
2.46 
(0.0626) 0.000929 
C4 
0 
NaN 
(NA) 0 
NaN 
(NA) 7 
1.85 
(0.401) 1 2.21 (NA) NaN 
R1 
28 
3.56 
(0.535) 10 
3.26 
(0.443) 9 
3.14 
(0.283) 1 2.1 (NA) 0.0288 
R2 
28 3.36 (0.6) 10 
2.96 
(0.375) 10 
2.81 
(0.384) 1 2.03 (NA) 0.013 
R3 
25 
3.04 
(0.569) 8 
2.59 
(0.311) 9 
2.23 
(0.439) 1 1.23 (NA) 0.000309 
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R4 
22 
2.23 
(0.512) 5 
1.62 
(0.367) 0 
NaN 
(NA) 0 NaN (NA) NaN 
Reference sample: variations of main segments 2D BSA-indexed 
diameters according to Dodge dominance in males. 
Main 
segments 
right small right balanced left p 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
n mean (SD) 
LM 
34 
2.24 
(0.322) 9 
2.07 
(0.332) 10 
2.62 
(0.46) 5 
2.37 
(0.396) 0.0478 
L1 
35 
1.86 
(0.374) 12 
1.9 
(0.317) 11 
1.99 
(0.274) 6 
1.85 
(0.169) 0.588 
L2 
35 
1.43 
(0.24) 12 
1.5 
(0.232) 11 
1.45 
(0.154) 6 
1.43 
(0.163) 0.783 
L3 
35 
0.981 
(0.2) 12 
1.04 
(0.162) 11 
1.09 
(0.183) 6 
1.13 
(0.176) 0.226 
L4 
27 
0.632 
(0.193) 9 
0.665 
(0.14) 10 
0.65 
(0.0941) 6 
0.778 
(0.0921) 0.123 
C1 
35 
1.56 
(0.343) 12 
1.76 
(0.177) 11 
2.15 
(0.584) 6 
1.94 
(0.313) 0.000536 
C2 
31 
1.13 
(0.372) 12 
1.38 
(0.387) 11 
1.62 
(0.368) 6 
1.69 
(0.314) 0.000917 
C3 
16 
0.707 
(0.253) 12 
0.968 
(0.234) 11 
1.33 
(0.466) 6 
1.23 
(0.134) 5.53e-05 
C4 
0 
NaN 
(NA) 0 
NaN 
(NA) 11 
0.995 
(0.384) 6 
0.95 
(0.167) NaN 
R1 
35 
2.12 
(0.35) 12 
1.97 
(0.211) 11 
1.78 
(0.32) 6 
1.45 
(0.0987) 4.92e-05 
R2 
35 
2.03 
(0.372) 12 
1.82 
(0.177) 11 
1.46 
(0.358) 6 
1.08 
(0.197) 4.15e-06 
R3 
35 
1.79 
(0.306) 12 
1.57 
(0.196) 10 
1.23 
(0.378) 6 
0.632 
(0.164) 1.76e-06 
R4 
35 
1.28 
(0.251) 12 
1.06 
(0.17) 0 NaN (NA) 0 NaN (NA) NaN 
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Reference sample: variations of main segments 2D BSA-indexed 
diameters according to Dodge dominance in females. 
Main 
segments 
right small right balanced left p 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
n mean (SD) 
LM 
33 
2.37 
(0.399) 10 
2.28 
(0.327) 10 
2.43 
(0.257) 2 2.7 (0.488) 0.562 
L1 
34 2.1 (0.35) 11 
1.87 
(0.351) 11 
1.92 
(0.345) 3 1.8 (0.302) 0.134 
L2 
34 
1.59 
(0.365) 11 
1.39 
(0.231) 11 
1.48 
(0.365) 3 
1.44 
(0.0791) 0.402 
L3 
34 
0.987 
(0.219) 10 
0.958 
(0.199) 11 
1.01 
(0.29) 3 
1.17 
(0.0742) 0.371 
L4 
23 
0.661 
(0.131) 8 
0.635 
(0.174) 9 
0.665 
(0.121) 3 
0.719 
(0.0595) 0.733 
C1 
34 
1.74 
(0.375) 11 
1.62 
(0.177) 11 
1.98 
(0.387) 3 
2.26 
(0.296) 0.0145 
C2 
31 
1.25 
(0.463) 10 
1.3 
(0.277) 11 
1.69 
(0.265) 3 
1.91 
(0.103) 0.00125 
C3 
19 
0.865 
(0.467) 10 
0.906 
(0.212) 11 
1.42 
(0.289) 3 1.6 (0.185) 0.000307 
C4 
0 
NaN 
(NA) 0 
NaN 
(NA) 11 
1.04 
(0.249) 3 
1.26 
(0.102) NaN 
R1 
34 
2.17 
(0.342) 11 
2.01 
(0.289) 11 
1.83 
(0.207) 3 
1.38 
(0.172) 0.000681 
R2 
34 
2.07 
(0.396) 11 
1.82 
(0.247) 11 
1.66 
(0.25) 3 
1.19 
(0.147) 0.000321 
R3 
34 
1.88 
(0.368) 11 
1.62 
(0.154) 11 
1.35 
(0.265) 3 
0.784 
(0.117) 1.14e-05 
R4 
34 
1.42 
(0.37) 11 
0.962 
(0.199) 0 
NaN 
(NA) 0 NaN (NA) 
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Reference sample: variations of main segments 3D BSA-indexed 
diameters according to Dodge dominance in males. 
Main 
segments 
right small right balanced left p 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
n mean (SD) 
LM 
29 
2.16 
(0.359) 8 
1.95 
(0.27) 7 
2.32 
(0.415) 4 
2.44 
(0.345) 0.147 
L1 
33 
1.83 
(0.335) 11 
1.78 
(0.262) 11 
1.86 
(0.302) 6 
1.81 
(0.155) 0.912 
L2 
31 
1.4 
(0.196) 11 
1.43 
(0.174) 11 
1.39 
(0.182) 6 1.4 (0.157) 0.867 
L3 
32 
0.947 
(0.184) 10 
1.06 
(0.175) 9 
1.04 
(0.161) 5 
1.11 
(0.166) 0.134 
L4 
17 
0.612 
(0.131) 6 
0.668 
(0.129) 5 
0.658 
(0.138) 4 
0.694 
(0.0874) 0.598 
C1 
32 
1.47 
(0.294) 11 
1.68 
(0.192) 10 
1.98 
(0.432) 6 
1.93 
(0.312) 0.000748 
C2 
25 
1.14 
(0.291) 11 
1.28 
(0.377) 10 
1.52 
(0.241) 6 
1.62 
(0.348) 0.00165 
C3 
11 
0.756 
(0.242) 9 
0.906 
(0.268) 10 
1.14 
(0.384) 5 
1.26 
(0.272) 0.00687 
C4 
0 
NaN 
(NA) 0 
NaN 
(NA) 6 
0.996 
(0.406) 3 
0.987 
(0.13) NaN 
R1 
29 
2.08 
(0.336) 11 
1.9 
(0.201) 11 
1.65 
(0.204) 5 
1.37 
(0.123) 1.05e-05 
R2 
30 
1.94 
(0.349) 10 
1.72 
(0.195) 10 
1.4 
(0.261) 5 1 (0.177) 3.34e-06 
R3 
26 
1.63 
(0.229) 10 
1.44 
(0.139) 9 
1.13 
(0.266) 5 
0.595 
(0.127) 2.34e-06 
R4 
25 
1.17 
(0.233) 8 
0.938 
(0.145) 0 
NaN 
(NA) 0 NaN (NA) NaN 
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Reference sample: variations of main segments 3D BSA-indexed 
diameters according to Dodge dominance in females. 
Main 
segments 
right small right balanced left p 
n mean 
(SD) 
n mean 
(SD) 
n mean (SD) n mean (SD) 
LM 
28 
2.29 
(0.278) 9 
2.25 
(0.271) 10 
2.51 
(0.348) 1 2.31 (NA) 0.254 
L1 
33 2 (0.248) 9 
1.88 
(0.306) 10 2 (0.217) 3 
1.8 
(0.342) 0.376 
L2 
34 
1.51 
(0.278) 9 
1.42 
(0.21) 10 1.54 (0.24) 3 
1.37 
(0.0947) 0.663 
L3 
33 
0.964 
(0.183) 9 
0.986 
(0.164) 10 
1.07 
(0.163) 3 
1.11 
(0.136) 0.247 
L4 
18 
0.633 
(0.13) 6 
0.708 
(0.194) 7 
0.701 
(0.0844) 1 
0.759 
(NA) 0.577 
C1 
34 1.7 (0.31) 10 
1.61 
(0.238) 11 
1.98 
(0.281) 3 
2.28 
(0.147) 0.0011 
C2 
29 
1.21 
(0.377) 10 
1.28 
(0.269) 10 
1.64 
(0.232) 3 
1.84 
(0.159) 0.00132 
C3 
13 
0.869 
(0.366) 8 
0.856 
(0.198) 9 1.42 (0.29) 3 
1.51 
(0.076) 0.00144 
C4 
0 
NaN 
(NA) 0 
NaN 
(NA) 7 
1.08 
(0.231) 1 1.35 (NA) NaN 
R1 
28 
2.07 
(0.333) 10 
1.92 
(0.244) 9 
1.87 
(0.249) 1 1.35 (NA) 0.0733 
R2 
28 
1.96 
(0.363) 10 
1.74 
(0.186) 10 
1.69 
(0.305) 1 1.31 (NA) 0.135 
R3 
25 
1.77 
(0.335) 8 
1.51 
(0.124) 9 
1.31 
(0.283) 1 
0.793 
(NA) 0.00136 
R4 
22 
1.31 
(0.338) 5 
0.914 
(0.222) 0 NaN (NA) 0 NaN (NA) NaN 
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Reference sample: variations of main segments 2D height-indexed 
diameters according to Dodge dominance in males. 
Main 
segments 
right small right balanced left p 
n mean 
(SD) 
n mean 
(SD) 
n mean (SD) n mean 
(SD) 
LM 
34 
2.47 
(0.396) 9 
2.41 
(0.376) 10 
2.97 
(0.446) 5 
2.63 
(0.36) 0.0135 
L1 
35 
2.05 
(0.413) 12 
2.17 
(0.323) 11 
2.25 
(0.274) 6 
2.07 
(0.226) 0.322 
L2 
35 
1.58 
(0.298) 12 
1.72 
(0.251) 11 
1.64 
(0.163) 6 
1.61 
(0.216) 0.387 
L3 
35 
1.08 
(0.236) 12 
1.19 
(0.19) 11 
1.23 
(0.196) 6 
1.27 
(0.238) 0.0761 
L4 
27 
0.699 
(0.232) 9 
0.762 
(0.169) 10 
0.737 
(0.0869) 6 
0.875 
(0.133) 0.13 
C1 
35 
1.73 
(0.412) 12 
2.01 
(0.208) 11 
2.42 
(0.589) 6 
2.17 
(0.331) 0.000143 
C2 
31 
1.25 
(0.428) 12 
1.58 
(0.45) 11 
1.83 
(0.392) 6 
1.89 
(0.359) 0.000496 
C3 
16 
0.785 
(0.29) 12 
1.1 
(0.242) 11 1.5 (0.484) 6 
1.38 
(0.166) 3.66e-05 
C4 
0 
NaN 
(NA) 0 
NaN 
(NA) 11 
1.12 
(0.395) 6 
1.07 
(0.207) NaN 
R1 
35 
2.33 
(0.36) 12 
2.25 
(0.152) 11 2.02 (0.38) 6 
1.63 
(0.127) 0.000159 
R2 
35 
2.23 
(0.383) 12 
2.08 
(0.166) 11 
1.66 
(0.444) 6 
1.21 
(0.221) 1.42e-05 
R3 
35 
1.97 
(0.306) 12 
1.79 
(0.219) 10 
1.39 
(0.441) 6 
0.708 
(0.185) 5.59e-06 
R4 
35 1.4 (0.26) 12 
1.21 
(0.203) 0 NaN (NA) 0 
NaN 
(NA) NaN 
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Reference sample: variations of main segments 2D height-indexed 
diameters according to Dodge dominance in females. 
Main 
segments 
right small right balanced left p 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
n mean (SD) 
LM 
33 
2.46 
(0.386) 10 
2.34 
(0.287) 10 
2.45 
(0.245) 2 2.8 (0.395) 0.479 
L1 
34 
2.18 
(0.342) 11 
1.91 
(0.348) 11 
1.95 
(0.377) 3 
1.83 
(0.307) 0.0488 
L2 
34 
1.65 
(0.355) 11 
1.43 
(0.24) 11 
1.5 
(0.386) 3 
1.46 
(0.0118) 0.216 
L3 
34 
1.03 
(0.227) 10 
0.985 
(0.209) 11 
1.02 
(0.302) 3 
1.18 
(0.0729) 0.444 
L4 
23 
0.692 
(0.153) 8 
0.651 
(0.164) 9 
0.677 
(0.141) 3 
0.732 
(0.097) 0.721 
C1 
34 
1.8 
(0.376) 11 
1.66 
(0.223) 11 
2.03 
(0.485) 3 
2.29 
(0.196) 0.0307 
C2 
31 1.3 (0.48) 10 
1.34 
(0.291) 11 
1.72 
(0.288) 3 
1.94 
(0.139) 0.00332 
C3 
19 
0.895 
(0.489) 10 
0.929 
(0.216) 11 
1.45 
(0.321) 3 
1.62 
(0.119) 0.000373 
C4 
0 
NaN 
(NA) 0 
NaN 
(NA) 11 
1.06 
(0.283) 3 
1.28 
(0.0996) NaN 
R1 
34 
2.25 
(0.332) 11 
2.06 
(0.269) 11 
1.87 
(0.245) 3 1.4 (0.159) 0.000114 
R2 
34 
2.15 
(0.392) 11 
1.86 
(0.233) 11 
1.68 
(0.254) 3 1.2 (0.109) 4.57e-05 
R3 
34 
1.95 
(0.371) 11 
1.66 
(0.164) 11 
1.37 
(0.284) 3 
0.794 
(0.0823) 2.78e-06 
R4 
34 
1.47 
(0.35) 11 
0.985 
(0.207) 0 
NaN 
(NA) 0 NaN (NA) NaN 
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Reference sample: variations of main segments 3D height-indexed 
diameters according to Dodge dominance in males. 
Main 
segments 
right small right balanced left p 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
LM 
29 
2.37 
(0.355) 8 
2.27 
(0.332) 7 
2.63 
(0.373) 4 
2.7 
(0.323) 0.118 
L1 
33 2 (0.341) 11 
2.04 
(0.263) 11 
2.11 
(0.305) 6 
2.02 
(0.153) 0.835 
L2 
31 
1.53 
(0.197) 11 
1.63 
(0.201) 11 
1.57 
(0.165) 6 
1.57 
(0.174) 0.394 
L3 
32 
1.04 
(0.198) 10 
1.21 
(0.21) 9 
1.17 
(0.162) 5 
1.24 
(0.231) 0.0767 
L4 
17 
0.674 
(0.16) 6 
0.773 
(0.155) 5 
0.736 
(0.121) 4 
0.777 
(0.13) 0.403 
C1 
32 
1.61 
(0.322) 11 
1.92 
(0.213) 10 
2.23 
(0.422) 6 
2.16 
(0.327) 6.37e-05 
C2 
25 
1.25 
(0.314) 11 
1.47 
(0.441) 10 
1.71 
(0.238) 6 
1.81 
(0.396) 0.000887 
C3 
11 
0.834 
(0.283) 9 
1.02 
(0.284) 10 
1.28 
(0.396) 5 
1.43 
(0.314) 0.00346 
C4 
0 NaN (NA) 0 NaN (NA) 6 
1.11 
(0.41) 3 
1.13 
(0.128) NaN 
R1 
29 
2.28 
(0.326) 11 
2.18 
(0.187) 11 
1.87 
(0.271) 5 
1.52 
(0.126) 6.22e-05 
R2 
30 
2.13 
(0.33) 10 
1.98 
(0.229) 10 
1.6 
(0.339) 5 
1.11 
(0.182) 1.45e-05 
R3 
26 
1.81 
(0.252) 10 
1.66 
(0.16) 9 
1.29 
(0.326) 5 
0.66 
(0.131) 4.01e-06 
R4 
25 
1.29 
(0.243) 8 
1.07 
(0.204) 0 NaN (NA) 0 
NaN 
(NA) NaN 
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Reference sample: variations of main segments 3D height-indexed 
diameters according to Dodge dominance in females. 
Main 
segments 
right small right balanced left p 
n mean 
(SD) 
n mean 
(SD) 
n mean (SD) n mean 
(SD) 
LM 
28 
2.39 
(0.246) 9 
2.31 
(0.266) 10 
2.52 
(0.237) 1 2.47 (NA) 0.402 
L1 
33 
2.08 
(0.238) 9 
1.93 
(0.298) 10 
2.03 
(0.187) 3 
1.83 
(0.33) 0.209 
L2 
34 
1.57 
(0.263) 9 
1.45 
(0.211) 10 
1.56 
(0.205) 3 
1.39 
(0.045) 0.402 
L3 
33 1 (0.193) 9 1 (0.164) 10 1.09 (0.14) 3 
1.12 
(0.0878) 0.379 
L4 
18 
0.656 
(0.146) 6 
0.717 
(0.186) 7 
0.694 
(0.0895) 1 
0.735 
(NA) 0.816 
C1 
34 
1.76 
(0.293) 10 
1.65 
(0.265) 11 
2.01 
(0.338) 3 
2.32 
(0.0924) 0.00413 
C2 
29 
1.26 
(0.386) 10 
1.32 
(0.29) 10 
1.67 
(0.242) 3 
1.87 
(0.216) 0.00228 
C3 
13 
0.904 
(0.388) 8 
0.882 
(0.191) 9 
1.45 
(0.294) 3 
1.53 
(0.0279) 0.00109 
C4 
0 
NaN 
(NA) 0 
NaN 
(NA) 7 
1.13 
(0.249) 1 1.37 (NA) NaN 
R1 
28 
2.16 
(0.299) 10 
1.97 
(0.246) 9 
1.91 
(0.211) 1 1.31 (NA) 0.0233 
R2 
28 
2.04 
(0.341) 10 
1.79 
(0.189) 10 
1.71 
(0.259) 1 1.27 (NA) 0.023 
R3 
25 
1.84 
(0.324) 8 
1.56 
(0.162) 9 
1.36 
(0.276) 1 
0.769 
(NA) 0.000212 
R4 
22 
1.35 
(0.307) 5 
0.968 
(0.238) 0 NaN (NA) 0 NaN (NA) NaN 
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Reference sample: scatterplot showing BSA-indexed L1 (proximal LAD) 
3D diameters variation according to Dodge dominances: right dominance 
(n = 66), small right dominance (n = 20), balanced dominance (n = 21), 
left dominance (n = 9). 
 
Reference sample: scatterplot showing BSA-indexed L1 (proximal LAD) 
3D diameters variation according to Dodge dominances; p = 0,484. 
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Reference sample: variations of main segments non-indexed diameters 
according to Syntax dominance in males. 
 2D p 3D p 
right left right left 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
LM 
53 
4.57 
(0.807) 5 
4.61 
(0.658) 0.9 44 
4.29 
(0.671) 4 
4.69 
(0.528) 0.235 
L1 
58 
3.78 
(0.698) 6 
3.68 
(0.491) 0.662 55 
3.63 
(0.584) 6 
3.58 
(0.372) 0.807 
L2 
58 
2.9 
(0.508) 6 
2.85 
(0.436) 0.772 53 
2.79 
(0.359) 6 
2.78 
(0.357) 0.931 
L3 
58 
2.03 
(0.423) 6 
2.25 
(0.463) 0.307 51 
1.96 
(0.375) 5 
2.18 
(0.416) 0.301 
L4 
46 
1.29 
(0.359) 6 
1.55 
(0.265) 0.0621 28 
1.26 
(0.286) 4 
1.38 
(0.262) 0.44 
C1 
58 
3.43 
(0.885) 6 
3.84 
(0.66) 0.203 53 3.2 (0.74) 6 
3.82 
(0.651) 0.0677 
C2 
54 
2.58 
(0.862) 6 
3.35 
(0.686) 0.0389 46 
2.51 
(0.68) 6 
3.21 
(0.754) 0.0716 
C3 
39 
1.95 
(0.778) 6 
2.45 
(0.37) 0.0222 30 
1.86 
(0.642) 5 
2.53 
(0.624) 0.0726 
C4 
11 
2.01 
(0.65) 6 
1.89 
(0.412) 0.663 6 
1.98 
(0.663) 3 2 (0.264) 0.926 
R1 
58 
4.03 
(0.644) 6 
2.88 
(0.269) 
2.19e-
06 51 
3.88 
(0.595) 5 
2.68 
(0.249) 
8.02e-
06 
R2 
58 
3.74 
(0.74) 6 
2.13 
(0.411) 
1.93e-
05 50 
3.56 
(0.643) 5 
1.94 
(0.281) 
2.32e-
06 
R3 
57 
3.27 
(0.687) 6 
1.25 
(0.311) 
4.57e-
08 45 
2.99 
(0.576) 5 
1.15 
(0.189) 1.5e-10 
Reference sample: variations of main segments non-indexed diameters 
according to Syntax dominance in females. 
 2D p 3D p 
right left right left 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
LM 
53 
4.01 
(0.567) 2 
4.51 
(0.676)  47 
3.97 
(0.411) 1 3.96 (NA)  
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L1 
56 
3.44 
(0.601) 3 
2.94 
(0.515) 0.229 52 
3.37 
(0.419) 3 
2.94 
(0.553) 0.313 
L2 
56 
2.6 
(0.574) 3 
2.35 
(0.0337) 0.00324 53 
2.54 
(0.419) 3 
2.23 
(0.0876) 0.00239 
L3 
55 
1.68 
(0.398) 3 1.9 (0.13) 0.0642 52 
1.67 
(0.313) 3 
1.8 
(0.147) 0.268 
L4 
40 
1.13 
(0.251) 3 
1.18 
(0.153) 0.634 31 
1.11 
(0.236) 1 1.18 (NA)  
C1 
56 
3.01 
(0.651) 3 
3.67 
(0.326) 0.0497 55 
2.95 
(0.536) 3 
3.72 
(0.176) 0.00239 
C2 
52 
2.3 
(0.724) 3 
3.11 
(0.206) 0.00228 49 
2.23 
(0.621) 3 
3.01 
(0.331) 0.0355 
C3 
40 
1.74 
(0.722) 3 2.6 (0.18) 0.000339 30 
1.75 
(0.634) 3 
2.46 
(0.0626) 1.8e-06 
C4 
11 
1.75 
(0.461) 3 
2.06 
(0.175) 0.105 7 
1.85 
(0.401) 1 2.21 (NA)  
R1 
56 
3.52 
(0.565) 3 
2.25 
(0.241) 0.00267 47 
3.41 
(0.503) 1 2.1 (NA)  
R2 
56 
3.3 
(0.648) 3 
1.93 
(0.164) 2.15e-05 48 
3.16 
(0.566) 1 2.03 (NA)  
R3 
56 
2.93 
(0.665) 3 
1.27 
(0.128) 1.54e-08 42 
2.78 
(0.599) 1 1.23 (NA)  
Reference sample: variations of main segments BSA-indexed diameters 
according to Syntax dominance in males. 
 2D p 3D p 
right left right left 
n mean 
(SD) 
n mean (SD) n mean 
(SD) 
n mean (SD) 
LM 
53 
2.28 
(0.387) 5 
2.37 
(0.396) 0.659 44 
2.15 
(0.364) 4 
2.44 
(0.345) 0.19 
L1 
58 
1.89 
(0.344) 6 
1.85 
(0.169) 0.618 55 
1.83 
(0.311) 6 
1.81 
(0.155) 0.828 
L2 
58 
1.45 
(0.223) 6 
1.43 
(0.163) 0.791 53 
1.4 
(0.186) 6 1.4 (0.157) 0.98 
L3 
58 
1.01 
(0.191) 6 
1.13 
(0.176) 0.185 51 
0.985 
(0.182) 5 
1.11 
(0.166) 0.169 
L4 
46 
0.643 
(0.164) 6 
0.778 
(0.0921) 0.0127 28 
0.632 
(0.13) 4 
0.694 
(0.0874) 0.272 
C1 
58 
1.71 
(0.433) 6 
1.94 
(0.313) 0.149 53 
1.61 
(0.362) 6 
1.93 
(0.312) 0.0541 
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C2 
54 
1.29 
(0.417) 6 
1.69 
(0.314) 0.0232 46 
1.26 
(0.333) 6 
1.62 
(0.348) 0.0507 
C3 
39 
0.964 
(0.407) 6 
1.23 
(0.134) 0.00433 30 
0.928 
(0.335) 5 
1.26 
(0.272) 0.0509 
C4 
11 
0.995 
(0.384) 6 
0.95 
(0.167) 0.741 6 
0.996 
(0.406) 3 
0.987 
(0.13) 0.964 
R1 
58 
2.03 
(0.343) 6 
1.45 
(0.0987) 
2.99e-
09 51 
1.95 
(0.332) 5 
1.37 
(0.123) 
4.97e-
06 
R2 
58 
1.88 
(0.398) 6 
1.08 
(0.197) 
8.18e-
06 50 
1.79 
(0.372) 5 1 (0.177) 
2.94e-
05 
R3 
57 
1.64 
(0.365) 6 
0.632 
(0.164) 
7.16e-
08 45 
1.49 
(0.291) 5 
0.595 
(0.127) 
2.71e-
07 
Reference sample: variations of main segments BSA-indexed diameters 
according to Syntax dominance in females. 
 2D p 3D p 
right left right left 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
LM 
53 
2.37 
(0.361) 2 
2.7 
(0.488)  47 
2.33 
(0.302) 1 2.31 (NA)  
L1 
56 
2.02 
(0.358) 3 
1.8 
(0.302) 0.326 52 
1.98 
(0.252) 3 
1.8 
(0.342) 0.47 
L2 
56 
1.53 
(0.347) 3 
1.44 
(0.0791) 0.228 53 
1.5 
(0.259) 3 
1.37 
(0.0947) 0.114 
L3 
55 
0.985 
(0.227) 3 
1.17 
(0.0742) 0.0216 52 
0.988 
(0.177) 3 
1.11 
(0.136) 0.26 
L4 
40 
0.657 
(0.135) 3 
0.719 
(0.0595) 0.202 31 
0.663 
(0.136) 1 
0.759 
(NA)  
C1 
56 
1.76 
(0.362) 3 
2.26 
(0.296) 0.091 55 
1.74 
(0.314) 3 
2.28 
(0.147) 0.00942 
C2 
52 
1.35 
(0.429) 3 
1.91 
(0.103) 0.000196 49 
1.31 
(0.368) 3 
1.84 
(0.159) 0.0106 
C3 
40 
1.03 
(0.439) 3 
1.6 
(0.185) 0.011 30 
1.03 
(0.394) 3 
1.51 
(0.076) 2.1e-05 
C4 
11 
1.04 
(0.249) 3 
1.26 
(0.102) 0.0453 7 
1.08 
(0.231) 1 1.35 (NA)  
R1 
56 
2.07 
(0.334) 3 
1.38 
(0.172) 0.0087 47 2 (0.309) 1 1.35 (NA)  
R2 
56 
1.94 
(0.382) 3 
1.19 
(0.147) 0.00221 48 
1.85 
(0.339) 1 1.31 (NA)  
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R3 
56 
1.72 
(0.38) 3 
0.784 
(0.117) 0.000124 42 
1.62 
(0.346) 1 
0.793 
(NA)  
Reference sample: variations of main segments height-indexed diameters 
according to Syntax dominance in males. 
 2D p 3D p 
right left right left 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
LM 
53 
2.55 
(0.443) 5 
2.63 
(0.36) 0.685 44 
2.39 
(0.362) 4 
2.7 
(0.323) 0.154 
L1 
58 
2.11 
(0.376) 6 
2.07 
(0.226) 0.731 55 
2.03 
(0.317) 6 
2.02 
(0.153) 0.926 
L2 
58 
1.62 
(0.27) 6 
1.61 
(0.216) 0.867 53 
1.56 
(0.192) 6 
1.57 
(0.174) 0.93 
L3 
58 
1.13 
(0.226) 6 
1.27 
(0.238) 0.232 51 
1.1 
(0.205) 5 
1.24 
(0.231) 0.231 
L4 
46 
0.72 
(0.196) 6 
0.875 
(0.133) 0.0348 28 
0.706 
(0.154) 4 
0.777 
(0.13) 0.374 
C1 
58 
1.92 
(0.494) 6 
2.17 
(0.331) 0.134 53 
1.79 
(0.402) 6 
2.16 
(0.327) 0.0402 
C2 
54 
1.44 
(0.48) 6 
1.89 
(0.359) 0.0257 46 
1.4 
(0.377) 6 
1.81 
(0.396) 0.0524 
C3 
39 
1.08 
(0.447) 6 
1.38 
(0.166) 0.00709 30 
1.04 
(0.368) 5 
1.43 
(0.314) 0.0463 
C4 
11 
1.12 
(0.395) 6 
1.07 
(0.207) 0.728 6 
1.11 
(0.41) 3 
1.13 
(0.128) 0.891 
R1 
58 
2.26 
(0.348) 6 
1.63 
(0.127) 
1.64e-
07 51 
2.17 
(0.328) 5 
1.52 
(0.126) 
2.91e-
06 
R2 
58 
2.09 
(0.418) 6 
1.21 
(0.221) 
1.24e-
05 50 
1.99 
(0.372) 5 
1.11 
(0.182) 
1.84e-
05 
R3 
57 
1.83 
(0.38) 6 
0.708 
(0.185) 
1.67e-
07 45 
1.67 
(0.318) 5 
0.66 
(0.131) 
6.05e-
08 
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Reference sample: variations of main segments height-indexed diameters 
according to Syntax dominance in females. 
 2D p 3D p 
right left right left 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
n mean 
(SD) 
LM 
53 
2.43 
(0.344) 2 
2.8 
(0.395)  47 
2.4 
(0.252) 1 
2.47 
(NA)  
L1 
56 
2.08 
(0.365) 3 
1.83 
(0.307) 0.278 52 
2.04 
(0.242) 3 
1.83 
(0.33) 0.376 
L2 
56 
1.58 
(0.349) 3 
1.46 
(0.0118) 0.0228 53 
1.54 
(0.245) 3 
1.39 
(0.045) 0.00288 
L3 
55 
1.02 
(0.236) 3 
1.18 
(0.0729) 0.0259 52 
1.02 
(0.18) 3 
1.12 
(0.0878) 0.16 
L4 
40 
0.68 
(0.15) 3 
0.732 
(0.097) 0.459 31 
0.677 
(0.142) 1 
0.735 
(NA)  
C1 
56 
1.82 
(0.388) 3 
2.29 
(0.196) 0.0349 55 
1.79 
(0.316) 3 
2.32 
(0.0924) 0.000461 
C2 
52 
1.39 
(0.442) 3 
1.94 
(0.139) 0.00315 49 
1.35 
(0.375) 3 
1.87 
(0.216) 0.0354 
C3 
40 
1.06 
(0.456) 3 
1.62 
(0.119) 0.000437 30 
1.06 
(0.402) 3 
1.53 
(0.0279) 5.9e-07 
C4 
11 
1.06 
(0.283) 3 
1.28 
(0.0996) 0.0569 7 
1.13 
(0.249) 1 
1.37 
(NA)  
R1 
56 
2.14 
(0.338) 3 
1.4 
(0.159) 0.0051 47 
2.07 
(0.289) 1 
1.31 
(NA)  
R2 
56 
2 
(0.389) 3 
1.2 
(0.109) 0.000104 48 
1.92 
(0.328) 1 
1.27 
(NA)  
R3 
56 
1.78 
(0.396) 3 
0.794 
(0.0823) 1.27e-07 42 
1.68 
(0.349) 1 
0.769 
(NA)  
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Reference sample: scatterplot showing BSA-indexed L1 (proximal LAD) 
2D diameters variation according to Syntax dominances: right 
dominance (n = 114), left dominance (n = 9). 
 
Reference sample: scatterplot showing BSA-indexed L1 (proximal LAD) 
3D diameters variation according to Syntax dominances: right 
dominance (n = 107), left dominance (n = 9). 
 
98 
 
Reference sample: variations of main segments 2D diameters according 
to gender. 
Coronar
y 
dominan
ce 
Main 
segme
nts 
Non-indexed 2D diameters BSA-indexed 2D diameters Height-indexed 2D 
diameters 
men wome
n 
p men wome
n 
p men wome
n 
p 
Syntax 
right 
LM 4.57 
(0.80
7) 
4.01 
(0.567
) 
8.11e-
05 
2.28 
(0.387
) 
2.37 
(0.361
) 0.254 
2.55 
(0.443
) 
2.43 
(0.344
) 0.117 
L1 3.78 
(0.69
8) 
3.44 
(0.601
) 
0.0062
5 
1.89 
(0.344
) 
2.02 
(0.358
) 0.052 
2.11 
(0.376
) 
2.08 
(0.365
) 0.693 
L2 2.9 
(0.50
8) 
2.6 
(0.574
) 
0.0032
2 
1.45 
(0.223
) 
1.53 
(0.347
) 0.161 
1.62 
(0.27) 
1.58 
(0.349
) 0.416 
L3 2.03 
(0.42
3) 
1.68 
(0.398
) 
1.45e-
05 
1.01 
(0.191
) 
0.985 
(0.227
) 0.465 
1.13 
(0.226
) 
1.02 
(0.236
) 
0.0086
2 
L4 1.29 
(0.35
9) 
1.13 
(0.251
) 0.0161 
0.643 
(0.164
) 
0.657 
(0.135
) 0.664 
0.72 
(0.196
) 
0.68 
(0.15) 0.296 
C1 3.43 
(0.88
5) 
3.01 
(0.651
) 
0.0043
3 
1.71 
(0.433
) 
1.76 
(0.362
) 0.504 
1.92 
(0.494
) 
1.82 
(0.388
) 0.247 
C2 2.58 
(0.86
2) 
2.3 
(0.724
) 0.0699 
1.29 
(0.417
) 
1.35 
(0.429
) 0.423 
1.44 
(0.48) 
1.39 
(0.442
) 0.58 
C3 1.95 
(0.77
8) 
1.74 
(0.722
) 0.222 
0.964 
(0.407
) 
1.03 
(0.439
) 0.505 
1.08 
(0.447
) 
1.06 
(0.456
) 0.773 
C4 2.01 
(0.65
) 
1.75 
(0.461
) 0.296 
0.995 
(0.384
) 
1.04 
(0.249
) 0.755 
1.12 
(0.395
) 
1.06 
(0.283
) 0.692 
R1 4.03 
(0.64
4) 
3.52 
(0.565
) 
1.93e-
05 
2.03 
(0.343
) 
2.07 
(0.334
) 0.443 
2.26 
(0.348
) 
2.14 
(0.338
) 0.0699 
R2 3.74 
(0.74
) 
3.3 
(0.648
) 
0.0011
3 
1.88 
(0.398
) 
1.94 
(0.382
) 0.378 
2.09 
(0.418
) 
2 
(0.389
) 0.233 
R3 3.27 
(0.68
7) 
2.93 
(0.665
) 
0.0096
2 
1.64 
(0.365
) 
1.72 
(0.38) 0.259 
1.83 
(0.38) 
1.78 
(0.396
) 0.484 
R4 2.41 
(0.46
8) 
2.22 
(0.613
) 0.0922 
1.22 
(0.25) 
1.31 
(0.389
) 0.204 
1.35 
(0.258
) 
1.35 
(0.382
) 0.945 
Dodge 
right 
LM 4.38 
(0.72
4) 
4.04 
(0.648
) 0.0445 
2.24 
(0.322
) 
2.37 
(0.399
) 0.14 
2.47 
(0.396
) 
2.46 
(0.386
) 0.867 
L1 3.64 
(0.77
) 
3.59 
(0.565
) 0.769 
1.86 
(0.374
) 
2.1 
(0.35) 
0.006
67 
2.05 
(0.413
) 
2.18 
(0.342
) 0.15 
L2 2.81 
(0.54
9) 
2.71 
(0.579
) 0.448 
1.43 
(0.24) 
1.59 
(0.365
) 
0.041
3 
1.58 
(0.298
) 
1.65 
(0.355
) 0.436 
L3 1.92 
(0.42
9) 
1.69 
(0.38) 0.0191 
0.981 
(0.2) 
0.987 
(0.219
) 0.915 
1.08 
(0.236
) 
1.03 
(0.227
) 0.302 
L4 1.24 
(0.41
4) 
1.15 
(0.26) 0.332 
0.632 
(0.193
) 
0.661 
(0.131
) 0.539 
0.699 
(0.232
) 
0.692 
(0.153
) 0.899 
C1 3.07 
(0.75
3) 
2.97 
(0.62) 0.558 
1.56 
(0.343
) 
1.74 
(0.375
) 
0.045
1 
1.73 
(0.412
) 
1.8 
(0.376
) 0.419 
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C2 2.23 
(0.76
1) 
2.13 
(0.765
) 0.615 
1.13 
(0.372
) 
1.25 
(0.463
) 0.279 
1.25 
(0.428
) 
1.3 
(0.48) 0.719 
C3 1.4 
(0.49
1) 
1.46 
(0.741
) 0.76 
0.707 
(0.253
) 
0.865 
(0.467
) 0.215 
0.785 
(0.29) 
0.895 
(0.489
) 0.417 
R1 4.14 
(0.68
5) 
3.71 
(0.563
) 
0.0052
8 
2.12 
(0.35) 
2.17 
(0.342
) 0.544 
2.33 
(0.36) 
2.25 
(0.332
) 0.337 
R2 3.96 
(0.68
3) 
3.54 
(0.658
) 0.0119 
2.03 
(0.372
) 
2.07 
(0.396
) 0.625 
2.23 
(0.383
) 
2.15 
(0.392
) 0.389 
R3 3.49 
(0.56
1) 
3.21 
(0.63) 0.0552 
1.79 
(0.306
) 
1.88 
(0.368
) 0.271 
1.97 
(0.306
) 
1.95 
(0.371
) 0.83 
R4 2.49 
(0.46
9) 
2.41 
(0.558
) 0.534 
1.28 
(0.251
) 
1.42 
(0.37) 
0.063
5 
1.4 
(0.26) 
1.47 
(0.35) 0.385 
Dodge 
small 
right 
LM 4.41 
(0.75
9) 
3.88 
(0.437
) 0.0916 
2.07 
(0.332
) 
2.28 
(0.327
) 0.185 
2.41 
(0.376
) 
2.34 
(0.287
) 0.647 
L1 3.91 
(0.58
3) 
3.16 
(0.591
) 
0.0061
2 
1.9 
(0.317
) 
1.87 
(0.351
) 0.841 
2.17 
(0.323
) 
1.91 
(0.348
) 0.0837 
L2 3.11 
(0.50
9) 
2.36 
(0.423
) 
0.0009
72 
1.5 
(0.232
) 
1.39 
(0.231
) 0.27 
1.72 
(0.251
) 
1.43 
(0.24) 
0.0096
2 
L3 2.16 
(0.39
8) 
1.63 
(0.362
) 
0.0039
1 
1.04 
(0.162
) 
0.958 
(0.199
) 0.304 
1.19 
(0.19) 
0.985 
(0.209
) 0.0265 
L4 1.38 
(0.35
4) 
1.08 
(0.259
) 0.0596 
0.665 
(0.14) 
0.635 
(0.174
) 0.707 
0.762 
(0.169
) 
0.651 
(0.164
) 0.191 
C1 3.63 
(0.40
8) 
2.76 
(0.43) 
6.65e-
05 
1.76 
(0.177
) 
1.62 
(0.177
) 
0.085
1 
2.01 
(0.208
) 
1.66 
(0.223
) 
0.0009
74 
C2 2.84 
(0.82
) 
2.22 
(0.537
) 0.0478 
1.38 
(0.387
) 
1.3 
(0.277
) 0.607 
1.58 
(0.45) 
1.34 
(0.291
) 0.154 
C3 1.99 
(0.41
5) 
1.54 
(0.382
) 0.0167 
0.968 
(0.234
) 
0.906 
(0.212
) 0.52 
1.1 
(0.242
) 
0.929 
(0.216
) 0.0913 
R1 4.06 
(0.26
8) 
3.4 
(0.46) 
0.0007
76 
1.97 
(0.211
) 
2.01 
(0.289
) 0.713 
2.25 
(0.152
) 
2.06 
(0.269
) 0.0524 
R2 3.76 
(0.32
1) 
3.09 
(0.422
) 
0.0004
33 
1.82 
(0.177
) 
1.82 
(0.247
) 0.986 
2.08 
(0.166
) 
1.86 
(0.233
) 0.0198 
R3 3.24 
(0.44
6) 
2.74 
(0.304
) 
0.0048
4 
1.57 
(0.196
) 
1.62 
(0.154
) 0.509 
1.79 
(0.219
) 
1.66 
(0.164
) 0.0994 
R4 2.2 
(0.40
4) 
1.63 
(0.34) 
0.0014
9 
1.06 
(0.17) 
0.962 
(0.199
) 0.224 
1.21 
(0.203
) 
0.985 
(0.207
) 0.0145 
Dodge 
balanced 
LM 5.35 
(0.71
) 
4.05 
(0.389
) 
0.0001
66 
2.62 
(0.46) 
2.43 
(0.257
) 0.277 
2.97 
(0.446
) 
2.45 
(0.245
) 
0.0064
1 
L1 4.06 
(0.46
8) 
3.22 
(0.607
) 
0.0018
9 
1.99 
(0.274
) 
1.92 
(0.345
) 0.603 
2.25 
(0.274
) 
1.95 
(0.377
) 0.0495 
L2 2.96 
(0.28
) 
2.48 
(0.64) 0.039 
1.45 
(0.154
) 
1.48 
(0.365
) 0.833 
1.64 
(0.163
) 
1.5 
(0.386
) 0.293 
L3 2.22 
(0.34
3) 
1.69 
(0.509
) 0.0101 
1.09 
(0.183
) 
1.01 
(0.29) 0.424 
1.23 
(0.196
) 
1.02 
(0.302
) 0.0709 
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L4 1.33 
(0.14
1) 
1.12 
(0.241
) 0.0363 
0.65 
(0.094
1) 
0.665 
(0.121
) 0.771 
0.737 
(0.086
9) 
0.677 
(0.141
) 0.288 
C1 4.35 
(0.95
1) 
3.36 
(0.814
) 0.0161 
2.15 
(0.584
) 
1.98 
(0.387
) 0.437 
2.42 
(0.589
) 
2.03 
(0.485
) 0.103 
C2 3.29 
(0.66
) 
2.84 
(0.493
) 0.0843 
1.62 
(0.368
) 
1.69 
(0.265
) 0.626 
1.83 
(0.392
) 
1.72 
(0.288
) 0.449 
C3 2.7 
(0.80
5) 
2.39 
(0.514
) 0.3 
1.33 
(0.466
) 
1.42 
(0.289
) 0.606 
1.5 
(0.484
) 
1.45 
(0.321
) 0.761 
C4 2.01 
(0.65
) 
1.75 
(0.461
) 0.296 
0.995 
(0.384
) 
1.04 
(0.249
) 0.755 
1.12 
(0.395
) 
1.06 
(0.283
) 0.692 
R1 3.64 
(0.69
7) 
3.08 
(0.386
) 0.0331 
1.78 
(0.32) 
1.83 
(0.207
) 0.634 
2.02 
(0.38) 
1.87 
(0.245
) 0.286 
R2 3.01 
(0.82
2) 
2.78 
(0.403
) 0.414 
1.46 
(0.358
) 
1.66 
(0.25) 0.155 
1.66 
(0.444
) 
1.68 
(0.254
) 0.904 
R3 2.51 
(0.81
5) 
2.26 
(0.477
) 0.412 
1.23 
(0.378
) 
1.35 
(0.265
) 0.417 
1.39 
(0.441
) 
1.37 
(0.284
) 0.911 
Syntax 
& 
Dodge 
left 
LM 4.61 
(0.65
8) 
4.51 
(0.676
) 0.875 
2.37 
(0.396
) 
2.7 
(0.488
) 0.501 
2.63 
(0.36) 
2.8 
(0.395
) 0.655 
L1 3.68 
(0.49
1) 
2.94 
(0.515
) 0.109 
1.85 
(0.169
) 
1.8 
(0.302
) 0.8 
2.07 
(0.226
) 
1.83 
(0.307
) 0.297 
L2 2.85 
(0.43
6) 
2.35 
(0.033
7) 0.0392 
1.43 
(0.163
) 
1.44 
(0.079
1) 0.882 
1.61 
(0.216
) 
1.46 
(0.011
8) 0.17 
L3 2.25 
(0.46
3) 
1.9 
(0.13) 0.137 
1.13 
(0.176
) 
1.17 
(0.074
2) 0.658 
1.27 
(0.238
) 
1.18 
(0.072
9) 0.451 
L4 1.55 
(0.26
5) 
1.18 
(0.153
) 0.0336 
0.778 
(0.092
1) 
0.719 
(0.059
5) 0.285 
0.875 
(0.133
) 
0.732 
(0.097
) 0.121 
C1 3.84 
(0.66
) 
3.67 
(0.326
) 0.626 
1.94 
(0.313
) 
2.26 
(0.296
) 0.204 
2.17 
(0.331
) 
2.29 
(0.196
) 0.531 
C2 3.35 
(0.68
6) 
3.11 
(0.206
) 0.453 
1.69 
(0.314
) 
1.91 
(0.103
) 0.174 
1.89 
(0.359
) 
1.94 
(0.139
) 0.803 
C3 2.45 
(0.37
) 
2.6 
(0.18) 0.455 
1.23 
(0.134
) 
1.6 
(0.185
) 
0.054
2 
1.38 
(0.166
) 
1.62 
(0.119
) 0.0547 
C4 1.89 
(0.41
2) 
2.06 
(0.175
) 0.432 
0.95 
(0.167
) 
1.26 
(0.102
) 
0.012
4 
1.07 
(0.207
) 
1.28 
(0.099
6) 0.0761 
R1 2.88 
(0.26
9) 
2.25 
(0.241
) 0.0187 
1.45 
(0.098
7) 
1.38 
(0.172
) 0.542 
1.63 
(0.127
) 
1.4 
(0.159
) 0.11 
R2 2.13 
(0.41
1) 
1.93 
(0.164
) 0.337 
1.08 
(0.197
) 
1.19 
(0.147
) 0.385 
1.21 
(0.221
) 
1.2 
(0.109
) 0.988 
R3 1.25 
(0.31
1) 
1.27 
(0.128
) 0.855 
0.632 
(0.164
) 
0.784 
(0.117
) 0.164 
0.708 
(0.185
) 
0.794 
(0.082
3) 0.367 
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Reference sample: scatterplots showing non-, BSA- and height-indexed 
main segments 2D diameters variation according to gender. 
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Reference sample: variations of main segments 3D diameters according 
to gender. 
Coronar
y 
dominan
ce 
Main 
segmen
ts 
Non-indexed 3D diameters BSA-indexed 3D diameters Height-indexed 3D 
diameters 
men wome
n 
p men wome
n 
p men wome
n 
p 
Syntax 
right 
LM 4.29 
(0.67
1) 
3.97 
(0.411) 
0.0075
5 
2.15 
(0.364) 
2.33 
(0.302) 0.0122 
2.39 
(0.36
2) 
2.4 
(0.252) 0.877 
L1 3.63 
(0.58
4) 
3.37 
(0.419) 
0.0093
4 
1.83 
(0.311) 
1.98 
(0.252) 
0.0057
9 
2.03 
(0.31
7) 
2.04 
(0.242) 0.797 
L2 2.79 
(0.35
9) 
2.54 
(0.419) 
0.0014
8 
1.4 
(0.186) 
1.5 
(0.259) 0.0255 
1.56 
(0.19
2) 
1.54 
(0.245) 0.716 
L3 1.96 
(0.37
5) 
1.67 
(0.313) 
7.58e-
05 
0.985 
(0.182) 
0.988 
(0.177) 0.945 
1.1 
(0.20
5) 
1.02 
(0.18) 
0.041
9 
L4 1.26 
(0.28
6) 
1.11 
(0.236) 0.0365 
0.632 
(0.13) 
0.663 
(0.136) 0.376 
0.706 
(0.15
4) 
0.677 
(0.142) 0.45 
C1 
3.2 
(0.74) 
2.95 
(0.536) 0.0547 
1.61 
(0.362) 
1.74 
(0.314) 0.0527 
1.79 
(0.40
2) 
1.79 
(0.316) 0.989 
C2 
2.51 
(0.68) 
2.23 
(0.621) 0.0422 
1.26 
(0.333) 
1.31 
(0.368) 0.443 
1.4 
(0.37
7) 
1.35 
(0.375) 0.517 
C3 1.86 
(0.64
2) 
1.75 
(0.634) 0.515 
0.928 
(0.335) 
1.03 
(0.394) 0.283 
1.04 
(0.36
8) 
1.06 
(0.402) 0.834 
C4 1.98 
(0.66
3) 
1.85 
(0.401) 0.701 
0.996 
(0.406) 
1.08 
(0.231) 0.668 
1.11 
(0.41) 
1.13 
(0.249) 0.888 
R1 3.88 
(0.59
5) 
3.41 
(0.503) 
5.71e-
05 
1.95 
(0.332) 
2 
(0.309) 0.433 
2.17 
(0.32
8) 
2.07 
(0.289) 0.107 
R2 3.56 
(0.64
3) 
3.16 
(0.566) 
0.0014
6 
1.79 
(0.372) 
1.85 
(0.339) 0.367 
1.99 
(0.37
2) 
1.92 
(0.328) 0.281 
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R3 2.99 
(0.57
6) 
2.78 
(0.599) 0.0972 
1.49 
(0.291) 
1.62 
(0.346) 0.06 
1.67 
(0.31
8) 
1.68 
(0.349) 0.865 
R4 2.21 
(0.46
1) 
2.12 
(0.539) 0.48 
1.12 
(0.236) 
1.24 
(0.353) 0.137 
1.24 
(0.25) 
1.28 
(0.328) 0.57 
Dodge 
right 
LM 4.2 
(0.63
6) 
3.94 
(0.417) 0.0643 
2.16 
(0.359) 
2.29 
(0.278) 0.136 
2.37 
(0.35
5) 
2.39 
(0.246) 0.809 
L1 3.55 
(0.62
3) 
3.43 
(0.425) 0.362 
1.83 
(0.335) 
2 
(0.248) 0.019 
2 
(0.34
1) 
2.08 
(0.238) 0.294 
L2 2.71 
(0.33
8) 
2.58 
(0.454) 0.184 
1.4 
(0.196) 
1.51 
(0.278) 0.0594 
1.53 
(0.19
7) 
1.57 
(0.263) 0.556 
L3 1.84 
(0.33
9) 
1.65 
(0.342) 0.0288 
0.947 
(0.184) 
0.964 
(0.183) 0.71 
1.04 
(0.19
8) 
1 
(0.193) 0.432 
L4 1.19 
(0.28
2) 
1.09 
(0.255) 0.272 
0.612 
(0.131) 
0.633 
(0.13) 0.625 
0.674 
(0.16) 
0.656 
(0.146) 0.742 
C1 2.85 
(0.59
2) 
2.9 
(0.496) 0.698 
1.47 
(0.294) 
1.7 
(0.31) 
0.0029
7 
1.61 
(0.32
2) 
1.76 
(0.293) 
0.054
5 
C2 2.22 
(0.54
3) 
2.07 
(0.624) 0.35 
1.14 
(0.291) 
1.21 
(0.377) 0.454 
1.25 
(0.31
4) 
1.26 
(0.386) 0.97 
C3 1.46 
(0.46
9) 
1.48 
(0.573) 0.942 
0.756 
(0.242) 
0.869 
(0.366) 0.378 
0.834 
(0.28
3) 
0.904 
(0.388) 0.612 
R1 4.05 
(0.59
9) 
3.56 
(0.535) 
0.0020
3 
2.08 
(0.336) 
2.07 
(0.333) 0.9 
2.28 
(0.32
6) 
2.16 
(0.299) 0.137 
R2 3.78 
(0.54
4) 
3.36 
(0.6) 
0.0078
3 
1.94 
(0.349) 
1.96 
(0.363) 0.892 
2.13 
(0.33) 
2.04 
(0.341) 0.29 
R3 3.22 
(0.46
5) 
3.04 
(0.569) 0.241 
1.63 
(0.229) 
1.77 
(0.335) 0.0984 
1.81 
(0.25
2) 
1.84 
(0.324) 0.691 
R4 2.29 
(0.44
4) 
2.23 
(0.512) 0.66 
1.17 
(0.233) 
1.31 
(0.338) 0.12 
1.29 
(0.24
3) 
1.35 
(0.307) 0.453 
Dodge 
small 
right 
LM 4.19 
(0.71
5) 
3.86 
(0.424) 0.278 
1.95 
(0.27) 
2.25 
(0.271) 0.0398 
2.27 
(0.33
2) 
2.31 
(0.266) 0.783 
L1 3.69 
(0.51
8) 
3.18 
(0.518) 0.0441 
1.78 
(0.262) 
1.88 
(0.306) 0.46 
2.04 
(0.26
3) 
1.93 
(0.298) 0.415 
L2 2.97 
(0.45
4) 
2.37 
(0.36) 
0.0042
9 
1.43 
(0.174) 
1.42 
(0.21) 0.976 
1.63 
(0.20
1) 
1.45 
(0.211) 
0.061
9 
L3 2.2 
(0.42
9) 
1.64 
(0.269) 
0.0035
4 
1.06 
(0.175) 
0.986 
(0.164) 0.366 
1.21 
(0.21) 
1 
(0.164) 
0.027
4 
L4 1.41 
(0.33
3) 
1.17 
(0.287) 0.2 
0.668 
(0.129) 
0.708 
(0.194) 0.687 
0.773 
(0.15
5) 
0.717 
(0.186) 0.586 
C1 3.48 
(0.43
3) 
2.73 
(0.469) 
0.0012
4 
1.68 
(0.192) 
1.61 
(0.238) 0.444 
1.92 
(0.21
3) 
1.65 
(0.265) 
0.019
9 
C2 2.66 
(0.82
2) 
2.19 
(0.543) 0.141 
1.28 
(0.377) 
1.28 
(0.269) 0.998 
1.47 
(0.44
1) 
1.32 
(0.29) 0.374 
C3 1.84 
(0.50
9) 
1.46 
(0.337) 0.0883 
0.906 
(0.268) 
0.856 
(0.198) 0.667 
1.02 
(0.28
4) 
0.882 
(0.191) 0.244 
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R1 3.95 
(0.38
1) 
3.26 
(0.443) 
0.0012
5 
1.9 
(0.201) 
1.92 
(0.244) 0.825 
2.18 
(0.18
7) 
1.97 
(0.246) 
0.044
4 
R2 3.6 
(0.48
5) 
2.96 
(0.375) 
0.0043
7 
1.72 
(0.195) 
1.74 
(0.186) 0.819 
1.98 
(0.22
9) 
1.79 
(0.189) 
0.059
2 
R3 3.01 
(0.32
7) 
2.59 
(0.311) 0.0136 
1.44 
(0.139) 
1.51 
(0.124) 0.303 
1.66 
(0.16) 
1.56 
(0.162) 0.211 
R4 1.95 
(0.44
5) 
1.62 
(0.367) 0.173 
0.938 
(0.145) 
0.914 
(0.222) 0.837 
1.07 
(0.20
4) 
0.968 
(0.238) 0.45 
Dodge 
balanced 
LM 4.77 
(0.64
9) 
4.16 
(0.358) 0.0511 
2.32 
(0.415) 
2.51 
(0.348) 0.341 
2.63 
(0.37
3) 
2.52 
(0.237) 0.527 
L1 3.8 
(0.52
5) 
3.33 
(0.256) 0.0192 
1.86 
(0.302) 
2 
(0.217) 0.267 
2.11 
(0.30
5) 
2.03 
(0.187) 0.498 
L2 2.83 
(0.25
7) 
2.57 
(0.327) 0.0574 
1.39 
(0.182) 
1.54 
(0.24) 0.135 
1.57 
(0.16
5) 
1.56 
(0.205) 0.932 
L3 2.1 
(0.27
3) 
1.78 
(0.24) 0.0172 
1.04 
(0.161) 
1.07 
(0.163) 0.718 
1.17 
(0.16
2) 
1.09 
(0.14) 0.247 
L4 1.32 
(0.18
6) 
1.13 
(0.144) 0.103 
0.658 
(0.138) 
0.701 
(0.084
4) 0.565 
0.736 
(0.12
1) 
0.694 
(0.089
5) 0.533 
C1 4 
(0.69
7) 
3.33 
(0.568) 0.027 
1.98 
(0.432) 
1.98 
(0.281) 0.979 
2.23 
(0.42
2) 
2.01 
(0.338) 0.22 
C2 3.07 
(0.39
5) 
2.75 
(0.394) 0.0859 
1.52 
(0.241) 
1.64 
(0.232) 0.266 
1.71 
(0.23
8) 
1.67 
(0.242) 0.7 
C3 2.31 
(0.66
1) 
2.4 
(0.432) 0.724 
1.14 
(0.384) 
1.42 
(0.29) 0.0877 
1.28 
(0.39
6) 
1.45 
(0.294) 0.315 
C4 1.98 
(0.66
3) 
1.85 
(0.401) 0.701 
0.996 
(0.406) 
1.08 
(0.231) 0.668 
1.11 
(0.41) 
1.13 
(0.249) 0.888 
R1 3.38 
(0.51
1) 
3.14 
(0.283) 0.199 
1.65 
(0.204) 
1.87 
(0.249) 0.0508 
1.87 
(0.27
1) 
1.91 
(0.211) 0.739 
R2 2.89 
(0.63
6) 
2.81 
(0.384) 0.745 
1.4 
(0.261) 
1.69 
(0.305) 0.0362 
1.6 
(0.33
9) 
1.71 
(0.259) 0.415 
R3 2.34 
(0.61
8) 
2.23 
(0.439) 0.688 
1.13 
(0.266) 
1.31 
(0.283) 0.182 
1.29 
(0.32
6) 
1.36 
(0.276) 0.64 
Syntax 
& Dodge 
left 
LM 4.69 
(0.52
8) 
3.96 
(NA) NaN 
2.44 
(0.345) 
2.31 
(NA) NaN 
2.7 
(0.32
3) 
2.47 
(NA) NaN 
L1 3.58 
(0.37
2) 
2.94 
(0.553) 0.169 
1.81 
(0.155) 
1.8 
(0.342) 0.986 
2.02 
(0.15
3) 
1.83 
(0.33) 0.419 
L2 2.78 
(0.35
7) 
2.23 
(0.087
6) 0.0123 
1.4 
(0.157) 
1.37 
(0.094
7) 0.732 
1.57 
(0.17
4) 
1.39 
(0.045) 
0.055
1 
L3 2.18 
(0.41
6) 
1.8 
(0.147) 0.119 
1.11 
(0.166) 
1.11 
(0.136) 0.977 
1.24 
(0.23
1) 
1.12 
(0.087
8) 0.334 
L4 1.38 
(0.26
2) 
1.18 
(NA) NaN 
0.694 
(0.087
4) 
0.759 
(NA) NaN 
0.777 
(0.13) 
0.735 
(NA) NaN 
C1 3.82 
(0.65
1) 
3.72 
(0.176) 0.742 
1.93 
(0.312) 
2.28 
(0.147) 0.0541 
2.16 
(0.32
7) 
2.32 
(0.092
4) 0.308 
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C2 3.21 
(0.75
4) 
3.01 
(0.331) 0.59 
1.62 
(0.348) 
1.84 
(0.159) 0.23 
1.81 
(0.39
6) 
1.87 
(0.216) 0.778 
C3 2.53 
(0.62
4) 
2.46 
(0.062
6) 0.825 
1.26 
(0.272) 
1.51 
(0.076) 0.109 
1.43 
(0.31
4) 
1.53 
(0.027
9) 0.509 
C4 2 
(0.26
4) 
2.21 
(NA) NaN 
0.987 
(0.13) 
1.35 
(NA) NaN 
1.13 
(0.12
8) 
1.37 
(NA) NaN 
R1 2.68 
(0.24
9) 
2.1 
(NA) NaN 
1.37 
(0.123) 
1.35 
(NA) NaN 
1.52 
(0.12
6) 
1.31 
(NA) NaN 
R2 1.94 
(0.28
1) 
2.03 
(NA) NaN 
1 
(0.177) 
1.31 
(NA) NaN 
1.11 
(0.18
2) 
1.27 
(NA) NaN 
R3 1.15 
(0.18
9) 
1.23 
(NA) NaN 
0.595 
(0.127) 
0.793 
(NA) NaN 
0.66 
(0.13
1) 
0.769 
(NA) NaN 
Reference sample: scatterplots showing non-, BSA- and height-indexed 
main segments 3D diameters variation according to gender. 
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Reference sample: scatterplot showing BSA-indexed L1 (proximal LAD) 
3D diameters variation according to gender: men (n = 61), women (n = 
55). 
 
Reference sample: point plot showing BSA-indexed L1 (proximal LAD) 
3D diameters variation according to gender; p =0,006. 
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CHAPTER 14 
Discussion and conclusion 
It is not that easy to justify a PhD program that covers all areas of 
interventional cardiology itself, in fact most researchers focus their 
scientific interests mainly on one or few main topics. However it must 
be said that these sectors present many interconnections between them, 
but also with other fields of medicine; for example, how could we good 
TAVI operators without being technically able to manage access site or 
coronary, as well as without possessing the necessary cultural 
background to manage potential periprocedural heart rhythm disorders 
or renal insufficiency? Although operators more than researchers have 
the ambition to range throughout all interventional cardiology, it should 
not be forgotten that research represents the basis for the development 
and improvement of all techniques, devices, drugs and skills. Facing an 
argument from the very beginning, which means from its definition, 
particularly from the definition of anatomical normality, is as 
uncommon as fundamental to acquire the right mindset to look at the 
coronary arteries from a perspective that is not only purely therapeutic. 
Collaboration with researchers whose scientific strengths belong to 
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different sectors of interventional cardiology can not help reinforcing 
and stimulating these ideas. It is for all these reasons that the research 
path started in the contest of my doctorate could be considered tiring 
and a bit distracting but in return absolutely educational for the open-
mindedness that all operators should acquire. 
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 In all the learning curves as well as the teaching processes, the 
common habit is to procede from simplest to most complex. 
Nevertheless medicine is not an exact science and consequently who 
could state if something is simpler than something else? In the recent 
periods, research in interventional cardiology is increasingly driven by 
commercial interests connected to new devices and drugs’ 
performances. Anyway an opposite pathway could be interesting and 
didactic at the same time. After analyzing the several complications of 
last generation structural and peripheral interventional procedures, 
researching about “normal” coronary arteries sizing has been an 
essential step of my PhD research pathway. Also if apparently this 
topic looks empiric, its clinical implications are numerous: the 
definition of normality will imply a more precise definition of 
coronary ectasia, and consequently a better knowledge of this disease. 
Such standardization will be the first stone to lay in order to identify 
the correct interventional or pharmacological treatment of this not so 
uncommon coronary disease. 
